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1. Introduction 
 
1.1. General introduction to bone marrow transplantation 
 
The transplantation of bone marrow (BM) is performed to reconstitute diseased or 
damaged hematopoietic systems in patients with malignant haematological diseases, e.g. 
leukaemia and lymphoma, congenital genetic disorders, e.g. thalassemia major (Thomas et 
al., 1982; Lucarelli et al., 1990; Giardini et al., 1999) or sickle cell disease (Bernaudin et 
al., 1999; Vermylen et al., 1998; Miller et al., 2000), autoimmune diseases, e.g. multiple 
sclerosis (Fassas et al., 2000; Mandalfino et al., 2000) or systemic sclerosis (Tyndall et al., 
2002), and patient with therapy-related toxicity after high-dose radio/chemotherapy to 
cure malignant solid tumors. While in the latter case and in some patients with 
haematological malignancy in complete remission, autologous bone marrow from the 
patient can be removed before, and given back after therapy, allogeneic bone marrow from 
a different individual has to be used in all other cases. Due to tissue incompatibility, the 
consequence of genetic differences between BM donor and recipient, such allogeneic bone 
marrow transplantation (BMT) may lead to severe immunological reactions known as 
graft-versus-host disease (GvHD). This immune response is a major cause of mortality 
after bone marrow transplantation. Patients with leukemia undergoing allogeneic as 
compared to autologous BMT, however, were shown to have a significantly reduced rate 
of tumor relapse, an effect known as graft-versus-leukemia response (GvL). Targets of 
GvHD and/or GvL responses are major and minor histocompatibility antigens, in which 
donor and patient differ. The development of methods to determine the major 
histocompatibility genotype of patients and volunteer BM donors, and the collection of 
this information in international registers, has greatly facilitated the rapid identification 
and selection of compatible bone marrow donors, and reduced the risk of severe immune 
responses due to disparities in major histocompatibility antigens. Minor histocompatibility 
antigens (mHA), in contrast, have remained largely unknown, which precludes mHA-
genotyping of patients and bone marrow donors. Molecular identification of mHA, 
furthermore, is required for the development of novel immunotherapeutic approaches to 
selectively enhance GvL, and reduce GvH responses.  
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1.2. Historical view on bone marrow transplantation 
 
 In 1949, Jacobson and co-workers noticed that mice could survive a normally 
lethal dose of ionizing irradiation when their spleens were shielded (Jacobson et al., 1949). 
Subsequently, it was reported that lethally irradiated mice could also survive when spleen 
or bone marrow cells were infused after irradiation (Lorenz et al., 1951). These 
experiments indicated that cells of the hematopoietic system are most susceptible to 
ionizing irradiation, and that the hematopoietic system can be reconstituted by the infusion 
of spleen or bone marrow cells. Infusion of bone marrow (BM) derived from a genetically 
different mouse strain, however, could cause an immune attack directed against the host. 
This immune reaction, which was found to be controlled by genetic factors (Uphoff, 
1957), resulted in a wasting syndrome known at that time as “secondary disease“ and 
today as graft-versus-host disease (GvHD) (van Bekkum and De Vries, 1967).  
 Subsequent studies in dogs provided important informations on applicability and 
feasibility of BMT in humans. First, it was shown that dogs could survive as much as two 
to four times the lethal dose of total body irradiation (TBI) (Mannick et al., 1960), when 
bone marrow cells were taken before and infused intravenously after irradiation. Second, 
bone marrow could be successfully transplanted in dogs treated with chemotherapy 
instead of TBI (Storb et al., 1969). Third, hematopoietic cells used in BMT could be 
obtained from BM as well as peripheral blood (Cavins et al., 1964). Fourth, the 
importance of leukocyte antigens in BMT, first established in mice, was also demonstrated 
in dogs. Animals receiving dog leukocyte antigen (DLA)-matched BM become healthy 
chimeras while DLA-mismatched BMT recipients usually died of graft rejection or GvHD 
(Epstein et al., 1968; Storb et al., 1971).  
 These results obtained in preclinical models inferred that successful BMT in 
humans was crucially dependent on the definition of human leukocyte antigens (HLA). As 
had been shown in animal models, these antigens may evoke immune responses after 
BMT. Serological HLA typing of patient and donor greatly reduced the risk of GvH 
responses. Accordingly, early attempts of BMT in humans failed because the patient died 
of GvHD (Mathe et al., 1965). The first successful human BMT was performed in a 
patient with severe combined immune deficiency in 1968 (Gatti et al., 1968). Two similar 
successful BMTs were reported at almost the same time (Bach et al., 1968; de Koning et 
al., 1969). Because of the diversity of HLAs, most BMTs were initially performed 
between sibling donor/recipient pairs. The introduction of immunosuppressive drugs, most 
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importantly cyclosporine A, ameliorated graft-versus-host immune reactions, and greatly 
improved clinical outcome of BMTs between unrelated patient/donor pairs (Storb et al., 
1988; Storb et al., 1989). In 1990s, molecular techniques were developed to precisely type 
HLA alleles, which then allowed the selection of HLA-matched unrelated BM donors 
(Thomas et al., 1999).  
 
1.3. Graft-versus-host (GvH) and graft-versus-leukemia (GvL) responses after 
allogeneic BMT 
 
 The reconstitution of BM in cancer patients treated with high dose chemo/radio -
therapy is a major indication for BMT. In these cases, BM is collected from the patient 
before, and given back after chemo/radio therapy. Because the patient’s own bone marrow 
is transplanted, this so-called autologous BMT is not associated with immunological 
rejection reactions. Autologous BMT, however, can not be performed in patients with 
genetic disorders or autoimmune diseases. In these cases allogeneic BM from a healthy 
donor must be used. With the rare exception of syngeneic BMT, where BM from a 
genetically identical twin is transplanted, the genetic differences between BM donor and 
recipient may evoke severe immunological complications after allogeneic BMT, known as 
graft-versus-host disease (GvHD) and host-versus-graft reaction (HvGR) resulting in BM 
rejection and graft failure. The main targets of these immune responses are HLA encoded 
by the major histocompatibility complex (MHC). Alloreactive T cells recognize non-self 
MHC molecules and may cause acute and often fatal immune reactions. While non-self 
MHC molecules are the main targets of the immune response after HLA-mismatched 
BMT, GvHD still occurs in more than half of the patients receiving HLA-identical BM 
from a sibling (Gratwohl et al., 2002; Sierra et al., 2002). In analogy to major 
histocompatibility antigens, the targets of the immune reaction under these circumstances 
have been designated minor histocompatibility antigens (mHA).  
Minor HA are gene products of polymorphic genetic loci, in which BM donor and 
recipient differ (Meadows et al., 1997; den Haan et al., 1998; Dolstra et al., 1999; Pierce et 
al., 1999; Warren et al., 2000). Peptides derived from mHA are presented by MHC class I 
and class II molecules on the cell surface where they can be recognized by donor-derived 
T cells (Fig. 1) (Sahara et al., 2003). Although the frequency of T cells specific for mHA 
is much lower then the frequency of alloreactive T cells recognizing non-self MHC 
molecules, and the elicited immune response against mHA is usually not as rapid and not 
_______________________________________________________________________________ 3
_________________________________________________          Introduction 
as vigorous as the allo-response (Goulmy et al., 1997; Warren et al., 1998), GvHD is still 
the major cause of mortality in these patients (Gratwohl et al., 2002). Removal of the T 
cells from grafted BM can prevent GvHD. However, such depletion increases the risk of 
graft failure (Kernan et al., 1989), and delayed immunological recovery (Marmont et al., 
1991). Furthermore, this immunological rejection reaction has also beneficial therapeutic 
effects. It is well documented that the rate of disease relapse is significantly lower in 
patients with leukemia receiving allogeneic as compared to syngeneic BM (Horowitz et 
al., 1990). These clinical observations suggest that the immune response associated with 
allogeneic BMT is also directed against residual tumor cells, an effect called graft-versus-
leukemia (GvL) response. This antitumoral effect of allogeneic BMT has recently led to 
clinical trials for the treatment of other malignancies eg. ovarian carcinoma (Bay et al., 
2000), and renal cell carcinoma (Childs et al., 1999; Childs et al., 2000; Rini et al., 2001) 
with high dose chemotherapy and subsequent allogeneic BMT. 
 
 1.4. Antigens involved in GvH and GvL response 
 
 Because GvL responses have been observed without any signs of GvHD (Slavin et 
al., 1990; Van Lochem et al., 1992; Falkenburg et al., 1993), the antigens recognized in 
these two types of immune responses are unlikely to be identical in all cases. In patients 
with leukemia receiving HLA-matched BM, three different types of antigens may lead to a 
GvL response without causing GvHD: leukemia-specific antigens, leukemia-associated 
antigens and hematopoiesis-specific mHA. 
  Leukemias often display characteristic chromosomal translocations, which may lead 
to the formation of tumor-specific fusion proteins. In the case of chronic myeloid leukemia 
(CML), this translocation involves chromosomes 9 and 22 and leads to the generation of 
the BCR/ABL fusion protein (Bocchia et al., 1995; Bosch et al., 1996; Berke et al., 2000). 
Peptides derived from this fusion protein can be presented by MHC class I and class II 
molecules on the cell surface, where they are recognized by CD8+ cytotoxic T cells (CTL) 
(Yotnda et al., 1998; Osman et al., 1999) or CD4+ T helper cells (Th) (Bocchia et al., 
1996). CTL recognition of BCR/ABL-derived peptides has been shown to eradicate CML 
cells in vitro (Yotnda et al., 1998; Norbury et al., 2000). Certain HLA molecules bind and 
present BCR/ABL peptides with high efficiency.  
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Fig.1 
 T cells involved in the immune response after allogeneic BMT. Three types of T 
cells can recognize MHC/antigen complexes presented on the surface of host tissues. First, 
alloreactive T cells recognize non-self MHC molecules on the surface of host cells and are 
responsible for the development of severe GvHD. These cells also recognize MHC/antigen 
complexes on tumor cells and cause their elimination. Second, tumor-specific T cells can 
recognize antigen exclusively (leukemia-specific antigens) or preferentially (leukemia-
associated antigens) expressed on tumor cells. These T cells cause specific destruction of 
residual tumor cells. Third, mHA-specific T cells recognize antigens expressed on the 
surface of normal as well as tumor cells. Therefore, mHA-specific T cells may cause 
GvHD and GvL responses. 
 
Because expression of these HLA has been associated with a lower risk of CML 
development (Posthuma et al., 1999; Posthuma et al., 2000), this correlation suggests that 
BCR/ABL-specific T cells are involved in protective immunity against CML. Immune 
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response against peptides spanning the junction of other fusion proteins, or tumor-specific 
mutations, have also been observed (Ohminami et al., 1999), but their contribution to 
immunological tumor control still needs to be established.  
Besides leukemia-specific antigens, leukemia-associated antigens may induce T cell 
responses as well. Tumor-associated antigens are either over- or aberrantly expressed in 
tumor cells. Proteinase-3 (PR-3), for example, is a serine protease normally expressed 
during myeloid differentiation and overexpressed in myeloid leukemias. Peptides derived 
from PR-3 are presented by HLA molecules and induce CTL responses, which 
preferentially lyse myeloid leukemia cells and specifically inhibit CML progenitor cell 
outgrowth (Molldrem et al., 1996; Molldrem et al., 1997). PR3-specific T cells have been 
detected after allogeneic BMT (Molldrem et al., 2000). The appearance of these cells has 
been associated with a more favourable prognosis, suggesting that donor-derived PR3-
specific CTL are involved in GvL responses. Other examples of leukemia-associated 
antigens include e.g. the products of the Wilm's tumor gene (WT-1), which is 
overexpressed in different types of leukemia (Ohminami et al., 2000; Oka et al., 2000; 
Gao et al., 2000), PRAME (Warren et al., 1998; Kessler et al., 2001), and the telomerase 
reverse transcriptase (TERT) (Minev et al., 2000; Nair et al., 2000).  
The third group of antigens recognized after HLA-identical allogeneic BMT is that 
of minor histocompatibility antigens (mHA). These include Y-chromosome encoded male-
specific antigens, which may evoke immune responses when BM from a female donor is 
transplanted into a male patient (Goulmy et al., 1997), as well as autosomally encoded 
mHA, derived from polymorphic genes (Goulmy et al., 1997). These mHA may also 
evoke immune responses after BMT when the proteins expressed from donor and recipient 
BM alleles differ in their amino acid sequences. Donor-derived T cells may recognize 
these differences because mHA, like all other cellular proteins, are presented on MHC 
molecules (den Haan et al., 1995; Meadows et al., 1997; Brickner et al., 2001). Depending 
on the tissue expression pattern, mHA may elicit GvHD and/or GvL responses. mHA 
expressed ubiquitously or in a variety of tissues may evoke immune responses against 
these tissues, and thus cause the symptoms of GvHD. Hematopoiesis-specific mHA may 
cause immune responses directed only against host-derived hematopoietic cells including 
residual tumor cells, and thus may contribute to tumor eradication, residual host 
hematopoietic cells elimination, and enhanced graft acceptance.  
The role of the three groups of antigens in the immune response after BMT has been 
elucidated by comparing clinical outcome after autologous, syngeneic and allogeneic 
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BMT. Compared to allogeneic BM recipients, patients undergoing autologous or 
syngeneic (between genetically identical twins) BMT have a higher risk of developing 
recurrent leukemia (Champlin et al., 1992). In the latter two cases, no major or minor 
histocompatibility differences exist, thus antitumoral immune responses are restricted to 
leukemia-specific and leukemia-associated antigens. The rate of disease relapse after 
HLA-identical sibling BMT versus syngeneic BMT for haematological malignancies was 
25% versus 46% in a study of Horowitz et al. (1990). In fact, in this trial, the relative risk 
of disease relapse was high for syngeneic BMT (2,09) while significantly lower for 
patients with HLA-identical sibling BMT (1,76-0,33), depending on T cell depletion 
(1,76) or evidence of acute (0,68), chonic (0,43), acute and chronic (1,0) or no GvHD 
(0,33). These results clearly demonstrate that recognition of minor histocompatibility 
antigens by T cells is most critical for GvHD and GvL responses after HLA-identical 
allogeneic BMT. 
 This notion is further supported by the effective treatment of leukemia relapse with 
the infusion of donor lymphocytes (DLI) (Kolb et al., 1990). In the initial study, DLI 
treatment of three patients with CML led to a complete tumor remission in all patients, but 
two of them developed GvHD. The importance of mHA in GvL response was further 
confirmed by the successful isolation of mHA-specific CTLs from BMT patients (Tsoi et 
al., 1980; Tsoi et al., 1983; Goulmy et al., 1983; Irle et al., 1985; Niederwieser et al., 1993; 
Goulmy et al 1997; Warren et al., 1998). These mHA-specific CTLs can effectively lyse 
leukemia cells and inhibit leukemia progenitor cell colony formation in vitro and in vivo 
(de Bueger et al., 1992; van der Harst et al., 1994; Dolstra et al., 1997; Bonnet et al., 1999; 
Nijmeijer et al., 2002). In order to enhance antitumoral responses after allogeneic BMT 
and reduce incidence and severity of GvHD, much effort has been put into the 
identification of mHAs. The rationale for their molecular identification is twofold: First, 
the selection of BM donors with a similar genotype in ubiquitously expressed mHA, and a 
greatly different genotype in hematopoiesis-specific mHA, is expected to reduce GvHD, 
and enhance GvL responses. Second, enhancing immune responses against hematopoiesis-
specific mHA by vaccination or the adoptive transfer of in vitro expanded T cells specific 
for these mHA, is expected to augment GvL responses without causing GvHD.   
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1.5. Identification of MHC class I-restricted mHAs 
     
 The development of cell culture techniques for the isolation and cultivation of 
mHA-reactive T cells has created the basis for the identification and molecular 
characterisation of the antigens recognized. A number of CD8+ mHA-specific T cell 
clones have been isolated from peripheral blood of patients after allogeneic BMT by 
different groups (van der Harst et al., 1994; Goulmy et al., 1997). In one study, 56 CD8+ 
mHA-specific T cell clones were isolated from ten patients with different hematopoietic 
malignancies after allogeneic BMT (Warren et al., 1998). These mHA-specific T cell 
clones recognized 17 different mHAs, of which 5 are expressed in both hematopoietic 
cells and fibroblasts, whereas 12 are expressed in hematopoietic cells only. Based on 
recognition pattern, HLA restriction and tissue expression, Goulmy and co-workers 
characterized CD8+ T cell clones that recognized seven different mHA (HA-1 to HA-7) 
(Goulmy et al., 1997). These studies indicated that a large number of mHAs with diverse 
tissue expression patterns and MHC restrictions exists.  
 mHA-specific T cells have been used to molecularly identify the antigens 
recognized. Up to now, all described mHA are recognised by CD8+ mHA-specific T cell 
clones isolated after allogeneic BMT. Two different approaches have been used for the 
molecular identification of MHC class I-restricted mHA, (i) biochemical peptide 
fractionation and (ii) a genetic cDNA expression cloning approach. 
 The biochemical peptide fractionation approach relies on the immune precipitation 
of the restricting MHC molecule from the surface of the cell line recognized by the mHA-
specific T cell clone. Subsequently, the peptides bound to the MHC molecules are eluted 
and fractionated by high performance liquid chromatography (HPLC). The peptide 
fractions are then tested in a recognition assay with mHA-specific CD8+ T cells and 
positive fractions are sequenced by mass spectroscopy. By comparing the sequence of the 
identified peptide with sequences in the DNA and protein database, the gene encoding the 
mHA can be identified. This method has been successfully used for the identification of 
HA-1, HA-2 (Den Haan et al., 1995; Den Haan et al., 1998) and HA-8 (Brickner et al., 
2001), SMCY (Meadows et al., 1997) and DFFRY (Pierce et al., 1999; Brickner et al., 
2001). 
 In the second approach, pools of a cDNA library derived from antigen-positive 
cells are transfected into antigen-negative target cells, together with the cDNA encoding 
the restricting MHC class I molecule. After expression of the transfected genes, peptides 
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derived from the gene products are presented by MHC class I molecules on the cell 
surface. Antigen containing cDNA pools are identified by co-culture of the transfected cell 
with the antigen-specific T cells. Recognition of the antigen by the T cells leads to 
cytotoxicity and the secretion of cytokines, both of which can be measured. Positive pools 
are subdivided and individual cDNAs tested in an identical fashion. This cDNA 
expression cloning method has been successfully used for the identification of the Y-
chromosome encoded UTY gene (Warren et al., 2000) and HB-1, which is selectively 
expressed in Epstein-Barr virus (EBV) transformed B cells (lymphoblastoid cell line, 
LCL) and B cell lymphoid leukemia (Dolstra et al., 1997). 
 
1.6. Identification of MHC class II restricted mHAs  
 
MHC class II-restricted CD4+ T cells play a central role in autoimmunity, 
infectious diseases, and antitumoral immune responses. An increasing number of 
evidences suggest an important role of CD4+ cells in GvHD and GvL responses after BMT 
(Russell et al., 2001). Animal models demonstrated that CD4+ T cells are required for 
sustained GvL responses and tumor eradication (Zeis et al., 2001). Furthermore, in MHC 
class I deficient mice, CD4+ T cells induce and maintain GvHD after HLA-matched 
allogeneic BMT (Shenoy et al., 1998). Recently, it has been shown that CD4+ donor 
lymphocyte infusions elicit potent allogeneic responses mediated by mHA-specific CD8+ 
T cells in humans (Zorn et al., 2002). Despite their importance in the immune responses 
after HLA-identical BMT, little is known about the antigens recognized by mHA-specific 
CD4+ T cells. Except for DBY, which was identified as the antigen recognized by a mHA-
specific CD4+ T cell clone by testing a small number of candidate genes (Scott et al., 
2000; Vogt et al., 2002), no other MHC class II-restricted mHA has been identified, 
mostly because generic methods for the molecular identification of these antigens are 
lacking. 
CD4+ T cells recognize peptides bound to MHC class II molecules at the surface of 
professional antigen presenting cells (pAPCs), like DC, macrophages, and B cells. In 
contrast to MHC class I bound peptides, peptides bound to MHC class II molecules are 
heterogeneous in length due to an open peptide-binding groove of these molecules.  
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Fig. 2 
Antigen presentation on MHC class I and II. Intracellular proteins are degraded by 
cytoplasmatic proteases e.g. the proteasome into peptides, which are transported by the 
transporter associated with antigen presentation (TAP) into the endoplasmatic reticulum, 
where peptides are loaded onto newly synthesized MHC class I molecules. These 
peptide/MHC complexes are then transported through the Golgi apparatus to the cell 
surface. Antigens presented on MHC class II are derived from internalised proteins that 
are degraded in the endosomal/lysosomal system. Newly synthesized MHC class II 
molecules are prevented from binding peptides in ER through their association with 
invariant chain, which also directs MHC class II molecules into the endosomal/lysosomal 
compartment. Within the lytic compartment, invariant chain is degraded, allowing 
peptides derived from exogenous proteins to bind to MHC class II. These peptide/MHC 
class II complexes are then transported to the cell surface (taken and modified from Nature 
Reviews Immunology).   
 
  
Thus, high performance liquid chromatography (HPLC) followed by mass spectroscopy of 
eluted peptides, as used for the identification of antigens recognized by CD8+ cells, cannot 
be applied for the identification of antigens presented on MHC class II molecules. 
Furthermore, a simple adaptation of the cDNA expression cloning approach used for the 
identification of MHC class I-restricted antigens is not possible for two reasons: First, 
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antigens presented on MHC class I are derived from intracellular proteins degraded by 
cytoplasmatic proteases like the proteasome. While, antigens presented on MHC class II 
molecules are mostly derived from exogenous proteins taken up by pAPC and cleaved into 
peptides by proteases in the endosomal/lysosomal compartment (Fig. 2). Second, pAPC 
are poorly transfectable, and therefore cannot serve as recipient cells for cDNA libraries.  
 Nevertheless, Wang et al. succeeded in adapting this approach for the 
identification of MHC class II-restricted tumor antigens (Wang et al., 1999). To overcome 
the differences in antigen presentation, libraries were constructed where the cDNAs were 
fused to the invariant chain gene. Due to the signal sequences present in the invariant 
chain, the resulting fusion proteins are directed into the endosomal/lysosomal 
compartment where processing and loading onto MHC class II molecules occurs (Wang et 
al., 1999; Sanderson et al., 1995; van Bergen et al., 1997; Fujii et al., 1998; Malcherek at 
al., 1998). As recipient cell line for the expression of cDNA libraries, highly transfectable 
293 cells (transformed human kidney embryonic cell line) were genetically modified to 
become artificial pAPC. The cells were stably transfected with cDNAs encoding DR and 
DR, which code for the appropriate MHC class II restriction element, DM and DM 
which help binding of peptides to MHC class II molecules, and invariant chain, which 
directs newly synthesized MHC molecules into the MHC class II processing and loading 
compartment. Using this approach two antigens recognized by melanoma-specific CD4+ 
cell lines were identified (Wang et al., 1999).  
 In addition, two tumor antigens recognized by tumor-specific CD4+ T cells have 
been identified through the biochemical purification of antigenic proteins from tumor 
lysates combined with mass spectrometric sequencing. Protein fractions obtained by 
biochemical separation methods are added to cultures of pAPC, which take-up, process 
and present these exogenous antigens on MHC class II, where they can be recognized by 
antigen-specific CD4+ T cells. Positive fractions are sequenced by mass spectroscopy and 
individual proteins tested separately. Because different proteins may exhibit different 
biochemical behaviour, this approach has to be tailored for each antigen, and is restricted 
to abundant antigens (Monach et al., 1995; Pieper et al., 1999).  
An indirect approach for the identification of tumor antigens recognized by T 
helper cells was described in 1995 and is based on the molecular identification of the 
antigens recognized by antibodies present in the serum of tumor patients (Sahin et al., 
1997). This method called SEREX (serological analysis of recombinant cDNA expression 
libraries) is a modification of a strategy developed earlier to assess humoral responses in 
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tumor patients (Old et al., 1981). The method is based on the concept that B cells require T 
cell help for switching their immunoglobulin (Ig) isotype. Antigen bound by IgM on the 
surface of naive B cells is internalized, processed and presented on MHC class II. If T 
helper cells recognize the antigen/MHC complex, they provide help to the B cells through 
the secretion of cytokines and the expression of membrane-bound ligands, which causes 
activation and differentiation into Ig-secreting B cells. Thus, high titer IgG antibody 
responses can only occur in the presence of T helper cells specific for the same antigen. In 
order to identify antigens recognized by serum IgG antibodies, a tumor-derived cDNA 
library is cloned into a λ phage expression vector. After infection of Escherichia coli, 
recombinant protein expression is induced and the expressed proteins are subsequently 
blotted onto nitrocellulose membranes and incubated with the serum of the patient. Serum 
antibodies bound to the proteins are detected with an enzyme linked secondary antibody 
specific for human IgG. The identity of the corresponding cDNAs can be obtained by 
sequence analysis of the λ phage coding for the antigen. It has been shown that many 
antigens recognized by serum antibodies are also targets of the T cell response and vice 
versa. For example, specific CD8+ and CD4+ responses have been observed in tumor 
patients with high titer antibodies against NY-ESO-1, a tumor-associated antigen 
identified with the SEREX method (Jäger et al., 2000; Zeng et al., 2001). These data 
suggested that SEREX-defined antigens might be a good indicator for T helper cell 
responses. 
 
1.7. Aim of the work 
 
Because generic methods for the identification of MHC class II-restricted antigens 
are not available, the aim of this work is to develop a novel approach for the efficient 
identification of mHA recognized by T helper cells.  
The correlation of humoral and cellular immune response observed in selected 
tumor patients had suggested that the identification of the targets of the antibody response 
may be useful to define the antigens against which a T helper cell response had been 
elicited. However, humoral and cellular immune responses had never been assessed with 
independent methods in these patients, leaving the question unanswered whether the 
targets of these two types of immune responses are identical, overlapping, or mostly 
diverse. Because simple methods to define the targets of the humoral immune response 
have been developed, the answer to this question has important implications for future 
_______________________________________________________________________________ 12
_________________________________________________          Introduction 
strategies to assess T helper cell responses. If a largely different set of antigens was 
identified with these two approaches, then indirect serological methods may be inadequate 
to define the antigens recognized by CD4 T cells, and can not substitute for direct methods 
to identify MHC class II-restricted antigens recognized by T helper cells. If the antigens 
identified with these two approaches are identical or overlapping, serological methods 
may be used for the identification of MHC class II-restricted antigens as long as generic 
direct methods are not available.  
To address this question, humoral and cellular immune responses should be 
assessed in parallel in a patient undergoing HLA-identical, allogeneic BMT. To identify 
the targets of the humoral immune response after BMT, the SEREX method originally 
developed to define the targets of the antibody response in cancer patients should be 
applied. Because mHA are the products of polymorphic genes, the successful adaptation 
of this method to BM recipients should result in the identification of antigens encoded by 
genes that differ between patient and BM donor. These candidate mHA should then be 
used in a recognition assay to test whether these polymorphic antigens are also recognized 
by mHA-specific T helper cells. To this end, efficient methods for the isolation and 
characterisation of the CD4+ mHA-specific T cell lines and clones should be developed to 
answer the question whether the targets of the humoral and the cellular immune response 
after BMT are identical or diverse. 
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2.  Materials and methods 
 
2.1. Materials 
 
If not stated otherweise, materials and reagents were obtained from the following 
companies: Amersham/Pharmacia Bioscience (Freiburg), Applied Biosystem 
(Weiterstadt), Becton Dickinson/Pharmingen (Heidelberg), BioRad (München), 
Calbiochem/Novabiochem (Beeston, Nottingham, UK), Costar (Bodenheim), Dianova 
(Hamburg), Difco (Difco Laboratories, Detroit, USA), Eppendorf (Hamburg), GLW 
(Würzburg), Greiner (Frickenhausen), ICN Biomedicals GmbH (Eschwege), Integra 
Bioscience GmbH (Fernwald), Labor Schubert & Weiß GmbH (München), Laborsystem 
Osvath (Geretsried), Life Technologies - Invitrogen (Karlsruhe), MBI-Fermentas (Vilnius, 
Lettland), Merck (E. Merck AG, Darmstadt), Millipore (Beedford, USA), NEB 
(Schwalbach), Neolab (Heildelberg), Nunc (Wiesbaden), Packard Instruments (Karlsruhe), 
Perkin Elmer/Applied Biosystems (Weiterstadt), Promega (Mannheim), Qiagen (Hilden), 
Roche/Boehringer (Mannheim), Roth (Karlsruhe), Sartorius (Göttingen), Sigma 
(Taufkirchen-München), Stratagene (Amsterdam). 
 
2.1.1. Commonly used material 
3MM paper Whatman, Maidstone, USA 
Bacteria und cell culture dishes Greiner, Frickenhausen 
Cryotubes  Nunc, Wiesbaden 
Cell culture Flasks (50, 250, 600 ml) Costar, Greiner, Nunc 
Elektroporation cuvettes BioRad, München 
Falcon, MultiwellTM 24 well plate Becton-Dickinson, Heidelberg 
Falcon, MultiwellTM 48 well plate Becton-Dickinson, Heidelberg 
Falcon, MicrotestTM 96 well plate Becton-Dickinson, Heidelberg  
FACS-tubes  Becton-Dickinson, Heidelberg 
JetStar Genomed, Bad Oeyenhausen 
Mikro-reactions tubes Eppendorf, Hamburg 
Parafilm  Dynatech, Denkendorf 
PCR-Purification-Kit Qiagen GmbH, Hilden 
Polypropylen tubes (5ml, 14ml)  Becton-Dickinson, Heidelberg 
Polypropylen tubes (15ml, 50ml)  Becton-Dickinson, Heidelberg 
Qiagen Plasmid Mini Kit Qiagen GmbH, Hilden 
Qiagen Plasmid Maxi Kit Qiagen GmbH, Hilden 
Qiaex II Gel Extraction Kit  Qiagen GmbH, Hilden 
RNeasy-Mini-Kit  Qiagen GmbH, Hilden 
Sterile filter (0,22µM, 0,45µM) Millipore, Eschborn 
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Disposable tissue culture dishes, culture bottles, culture- and test tubes were purchased 
from Nunc GmbH, Wiesbaden; Beckton Dickinson, Heidelberg; Greiner GmbH, 
Frickenhausen, Nürtlingen; or Corning Glassworks, NY. Glassware was from Corning 
Glassworks, NY, and Fisher Scientific, Fair Lawn, NJ. Conical 1,5 ml centrifuge tubes 
were manufactured by Eppendorf, BioRad or Sarstedt. Other general supplies, including 
pipets, test tubes, filter papers, syringes, and sterile filtration units were obtained from 
Fisher Scientific. 
 
2.1.2. Chemicals and biological reagents 
 
Agarose     Life Technologies – Invitrogen, Karlsruhre  
Amphotericin B    Life Technologies – Invitrogen, Karlsruhre 
Bromophenol Blue    IBI, New Haven, CN, USA 
BSA       Sigma –Aldrich, Taufkirchen 
Chloroform     Merck, Darmstadt 
DMEM      Life Technologies – Invitrogen, Karlsruhre  
DMSO      Sigma –Aldrich, Taufkirchen 
EDTA      Sigma –Aldrich, Taufkirchen 
Ethidium bromide    Merck, Darmstadt 
Ethanol      Merck, Darmstadt 
Ficoll-Paque      Amersham-Pharmacia, Freiburg 
Fetal calf serum, (FCS)    Life Technologies – Invitrogen, Karlsruhre 
      Biochrom, Berlin 
      Bioser, Buenos Aires 
L- Glutamine     Life Technologies – Invitrogen, Karlsruhre 
Glycerol     Sigma –Aldrich, Taufkirchen 
Glycine      Sigma –Aldrich, Taufkirchen 
HEPES      Sigma –Aldrich, Taufkirchen 
Hybond-C blotting membrane    Amersham-Pharmacia, Freiburg 
Hydrochloric acid     Merck, Darmstadt 
Isopropanol     Merck, Darmstadt 
Magnesium chloride    Sigma –Aldrich, Taufkirchen 
Mycoplasma removal agent               ICN Biomedicals GmbH, Eschwege 
Phenol      Merck, Darmstadt 
Potassium chloride    Fluca Chemie AG, Buchs, CH 
Propidium iodide    Sigma –Aldrich, Taufkirchen 
RNase A     Roche/Boehringer, Mannheim 
RPMI 1640     Life Technologies – Invitrogen, Karlsruhre  
SDS      Merck, Darmstadt 
Sodium acetate     Merck, Darmstadt 
Sodium chloride    Merck, Darmstadt 
Sodium hydroxide    Merck, Darmstadt 
TEMED      Merck, Darmstadt 
Tris        Sigma –Aldrich, Taufkirchen 
Trypsine     Life Technologies – Invitrogen, Karlsruhre 
Tween 20     Sigma –Aldrich, Taufkirchen 
Whatman 3MM-paper    Whatman, Maidstone, England, UK 
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2.1.3. Solutions, buffers and media 
 
10x STE   1 M NaCl; 200 mM Tris-Cl pH 7,5; 100 mM EDTA in H2O, autoclaved 
 
TBS 20 mM Tris-Cl pH 7,5; 150 mM NaCl in H2O 
 
TBST TBS + 0,05% (v/v)Tween 20  
 
1xTE 10 mM Tris-Cl pH 7,5; 1 mM EDTA in H2O 
 
x-gal  40 mg/ml x-gal (5-Bromo-4-Chloro-3-Indoyl--D Galactopyranosid) 
dissolved in DMF; sterile filtrated 
 
10× MOPS Buffer 200 mM MOPS (3-[N-morpholino]propane-sulfonic acid); 50 mM 
sodium acetate; 10 mM EDTA. PH was adjusted to 6.5–7.0 with NaOH 
 
50x TAE 2 M Tris Base; 50 mM EDTA pH 8,5 in H2O 
 
Ethidiumbromide-Solution 10 mg/ml in ddH2O 
 
Formaldehyde Gel  
loading buffer            720 µl of formamide; 160 µl of 10× MOPS buffer; 260 µl of 37% 
formaldehyde; 100 µl of sterile water; 100 µl of EtBr (10 mg/ml); 80 µl 
of sterile glycerol; 80 µl of saturated bromophenol blue (BPBll) in 
sterile water 
 
LB Agar  10 g of NaCl; 10 g of tryptone; 5 g of yeast extract; 20 g of agar. 
Deionized H2O was added to a final volume of 1 liter and pH adjusted to 
7.0 with 5 N NaOH. Medium was autoclaved and poured into petri 
dishes (~25 ml/100-mm plate) 
 
LB media 10 g of NaCl; 10 g of tryptone; 5 g of yeast extract. Mixture was 
dissolved in deionized H2O to a final volume of 1 liter. pH was adjusted 
to 7.0 with 5 N NaOH, autoclaved, and used with appropriate antibiotics 
 
SM Buffer  5.8 g of NaCl; 2.0 g of MgSO4 · 7 H2O; 50 ml of 1 M Tris-HCl (pH 7.5); 
5.0 ml of 2% (w/v) gelatin. Deionized H2O was added to a final volume 
of 1 liter 
 
20× SSC Buffer  175.3 g of NaCl; 88.2 g of sodium citrate; 800 ml of deionized H2O. pH 
was adjusted to 7.0 with a few drops of 10 N NaOH and deionized H2O 
was added  to a final volume of 1 liter 
 
Super Broth  35 g of tryptone; 20 g of yeast extract; 5 g of NaCl were dissolved in 
deionized H2O to a final volume of 1 liter.  Upon adjustment of pH to 
7.5 with 5M NaOH, medium was autoclaved. 
 
FACS-buffer   BSA (Bovine serum albumine) 0.2% in PBS 
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2.1.4. Antibiotics 
 
 
Ampicillin 100mg Ampicillin (Merck, Darmstadt) was dissolved in 10ml 70% 
ethanol and used at 100 µg/ml. 10 mg/ml solution was stored at -20˚ C 
 
Kanamycin 100mg Kanamycin (Merck, Darmstadt) was dissolved in 10ml ddH2O 
and used at 50 µg/ml. 10 mg/ml solution was stored at -20˚ C 
 
Tetracyclin 100mg Tetracyclin (Merck, Darmstadt) was dissolved in 10ml of 70% 
ethanol and used at 12,5 µg/ml. 10 mg/ml solution was stored at -20˚ C 
  
 
2.1.5. Oligonucleotides (Primers) 
 
 
All oligonucleotides were synthesised by Metabion GmBH, Martinsried. 
 
 
 
Clone 
number Primer 5’→3’ orientation 
sense primer I  agacattgctgtctggtg  
antisense primer I  aactggccactgtttgca  
sense primer II  caagagagtggcagacat  
2-1 
 
antisense primer II   tgcgattcttccgtgact  
sense primer    gcagaatggctcccgcaa  2-2 
antisense primer  cagcgattagttctcatcca  
sense primer   ttcagcgcatggacaccac  
antisense primer  cacagggatagatttatgcag  
sense primer I  ggacatactacatggatcag  
antisense primer I  cacttgatgaggtactggat  
sense primer II  cctagtggtgactttgacac  
antisense primer II  aggagcctatggttggactt 
sense primer III   gaagcccatcggttgaagaa  
antisense primer III  ttgagttggaccttcctgag  
sense primer IV  ggagaggtccaacaatcaag  
8 
 
antisense primer IV  tggacttttttccaagccatc  
sense primer   tgtgcttctactgaggactg  10-2 
 antisense primer  cgctggtcccatgctcag  
sense primer I  tagaagacttccgcgtaacc  
antisense primer I  atggtttcgaagacctcctc  
sense primer II  atctccaagagccagtctct  
10-1 
 
antisense primer II  cagatctaattggatcgggc  
sense primer   ttataggtagaggcgacaga  20-1 
 antisense primer  atgctacctttgcacggtta  
sense primer I  ggccacagccagcatgca  
antisense primer I  aggatgacggtgctgcgta  
sense primer II  gactacaagctccggccat  
21-1 
 
antisense primer II  tggtggtggcactgtctca  
sense primer   tctgggtggccatggag  22-1 
 antisense primer  cttgttcctgccagcatt  
sense primer   aca ggtaccatgaaggtctc  22-2 
 antisense primer  aggttcaaggactctccatc  
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sense new  agagctcagctcctcacca  22-3 
 antisense new  tctgacactctcaggatgtg  
sense primer   agagcctagaggatgtttca    31 
 antisense primer  ccatcgcctcagactctg  
sense primer   gaagatggcggacattca  64-2 
 antisense primer  atgtccagcctcagaact  
sense primer   tcagaagcagtcctttgagc  65-2 
antisense primer  aactggctctctcaagctga  
sense primer I  tcacatcgaacatgtggtgc  
antisense primer I  gataccatctcctgctgctt  
sense primer II  gacagattcaaggccactg  
69 
antisense primer II  ccagtcctaaggaacagag  
sense primer   cctaggtcacggcaatca  116 
 antisense primer  cctgctgcctcttctaat  
sense primer I  cgataagaagtcctcctg  
antisense primer I  cttcaggagatgagaagc  
sense primer II  gctaaggtaatgctggag  
120-1 
 
antisense primer II  aggtccataggacaagct  
sense primer   gcgggattctgacttaga  120-2 
 antisense primer  caggtggggagtttgac  
sense primer I  gccgagatggggctgc  
antisense primer I  gcctgtagagtgcaactg  
sense primer II  agatcacattccctgcaca  
133-2 
 
 
antisense primer II  aaggaatggtttagcgcca  
sense primer I  tgaccagccgcaagatgg  
antisense primer I  aagcgactctgggttcttg  
sense primer II  agcccgaccagtaccaga  
209 
 
 
 antisense primer II  agagaaggcagtatcccag  
sense primer   atggaagccttggggttt  216 
 antisense primer  tcagcgggatacgatctt  
sense primer   cagaacacaggtgtcgtgaa  233 
 antisense primer  accgttcttccaccactgat  
 
 
 
 
2.1.6. Peptides 
 
All peptides were synthesised by Metabion GmBH, Martinsried. The purity of the peptides 
was greater than 90%. 
 
 
Name Sequence BMT 
Peptide 10-1 TQSVPVRCPARRRQS    before (patient) 
Control peptide 10-1 TQSVPVRRPARRRQS    after    (donor) 
Peptide 10-2 DVRIWPLDPSLLGEP    before (patient) 
Control peptide 10-2 DVRIWPLHPSLLGEP after    (donor) 
Peptide 21-1 GWYTYMLLPAALTGL before (patient) 
Control peptide 21-1 GWYTYMLVPAALTGL after    (donor) 
Control peptide 22 QQTQVAASGGAGRAA before (patient) 
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2.1.7. Antibodies 
 
Antibody Antigen  
Alkaline Phosphatase-conjugated 
AffiniPure Goat Anti-Human IgG 
IgG, Fcγ 
Fragment specific 
PE labelled goat Anti-mouse IgM and IgG, Fab Fragment 
specific 
Dianova, 
Hamburg 
Monoclonal Anti-Human HLA Class I Antigene (clone 
W6/32) Sigma-Aldrich 
Purified Anti-Human HLA-DR (clone L243) 
PE labelled Anti-Human CD4 
FITC labelled Anti-Human CD8 
CD16 
CD45RO 
CD62L 
TCR αβ 
Purified Anti-Human 
TCR γδ 
Pharmingen, 
Becton 
Dickinson 
(Heidelberg) 
 
 
 
 
 
2.1.8. Bacterial strains 
 
E. coli XL1-Blue MRF‘  (Stratagene, La Jolla, CA) (Jerpseth et al., 1992) Genotyp: ∆(mcrA)183, 
∆(mcrCB-hsdSMR-mrr)173, endA1, supE44, thi-1, recA1, gyrA96, 
relA1, lac, [F’proAB lacqZ ∆ M15 Tn10 (Tetr)]c. Used as host strain for 
λ-phages in all steps including titration, blue-white-selection, 
amplification, screening with serum except propagation of filamentous 
phages. 
 
E. coli SOLR  (Stratagene, La Jolla, CA) (Hay & Short, 1992) Genotyp: E14-(McrA-), 
∆ mcrCB-hsdSMR-mrr)171, sbcC, recB, recJ, uvrC, umuC::Tn5, (Kanr), 
lac, gyrA96, relA1, thi-1, endA1, λR, [F’proAB lacqZ∆M15]c. Used as 
host strain for packed phagmides after excision. 
 
 
2.1.9. Bacteriophages 
 
Lambda ZAP® II  (Stratagene, La Jolla, CA) (Short et al., 1988) Expression vector system 
with capacity to accommodate DNA inserts up to 10 kb in length in 21 
unique cloning sites inside of lacZ-gene. The vector system is suitable 
for library screening with DNA probes or antibodies and allows in vivo 
excision of the pBluescript phagemide together with inserts. 
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ExAssist™ Interference- 
Resistant Helper Phage (Stratagene, La Jolla, CA) (Hay & Short, 1992) The helper phage 
carrying amber mutations and is used for pBluescript-plasmids excision 
from -ZAP® II-library. 
 
2.1.10. Enzymes 
 
If not stated otherwise, all enzymes including T4-DNA-polymerase, CIP, T4-DNA-ligase, 
reverse-transcriptase and adequate buffers were from New England Biolabs (Schwalbach) 
and MBI Fermentas (Vilnius, Lettland). Taq, PFU polymerase and corresponding buffers 
were from Promega (Mannheim). 
 
2.1.11. DNA standard 
 
Gene-Ruler (1kb DNA Ladder) standard (MBI Fermentas) has been used for DNA-
agarose-gelelectrophoresis. 
 
2.1.12. Software 
 
Clone manager 6 program (Scientific and educational software) was used for DNA 
sequence and plasmide analysis. After FACS measurements Cell quest software (Becton-
Dickinson) and WinMDI 2.8 (J. Trotter; Scripps Research Institute, LA Jolla, CA; 
http:/facs.scripps.edu/) have been used for analysis of the obtained results. For optical 
density measurements in ELISA assays Xread Plus (Tecan Deutschland GmbH, 
Creilsheim) and Microsoft Excel (Microsoft, USA) were used. Processing and data 
compilation were performed on a PC computer using Microsoft Word programme.  
 
2.1.13. Equipment 
 
The CO2 incubator used in these studies was manufactured by Heraeus. Sorvall and 
Beckman refrigerated floor model centrifuges were used for moderate speed 
centrifugations. Hettich centrifuges were used for low speed cell pelleting. An Eppendorf 
microcentrifuge was utilized in nucleic acid manipulations and for other experiments 
using 1.5 ml conical test tubes. General-purpose water baths and shaker tables were used 
in various functions. Beckman spectrophotometer was used to determine nucleic acid 
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concentrations, as well as bacterial optical density. FACS analysis was performed on the 
FACScan, supplied by Becton Dickinson. Microliter pipets manufactured by Gilson were 
used throughout this work.  
 
Bacteria-incubator    Haereus, Osterode 
Bacteria shaker      New Brunswick Scientific, Edison, USA 
Cell counting chamber     GLW, Würzburg 
Centrifuge 5415C     Eppendorf, Hamburg 
Centrifuge      Sepatech Variofuge Haereus 
Centrifuge 2K15      Sigma –Aldrich, Taufkirchen 
CO2-Incubator, Haereus 6000    Haereus, Osterode 
Elektroporation equipment Gene Pulser II  BioRad, München 
ELISA-Reader      Tecan Deutschland GmbH, Creilsheim  
FACS-Scan equipment    Becton-Dickinson, Heidelberg 
Gel electrophoresis chamber   Life Technologies – Invitrogen, Karlsruhre 
Light-optical microscope     Axiovert 135, Carl Zeiss, Stuttgart 
Milli-Q water preparation equipment  Millipore, Essen 
pH-Meter Multi-Calimatic 763    Knick, Engelsbach 
Pipettes (20, 200, 1000µl)    Gilson, Netherlands 
Pipett Boy     Integra Bioscience GmbH, Fernwald 
Power supply Power-Pac 300    BioRad, München 
Scanner       Epson GT 9600, Epson, Düsseldorf 
Spectrophotometer (BioPhotometer)   Eppendorf, Hamburg  
Sterile bench (Lamina Flow Hood)    Bio Flow Technik, Meckenheim 
UV-Transilluminator     UVP Inc., San Gabriel, USA 
Vortex Genie 2     Bender & Hobein, Ismaning 
 
 
 
2.2. Methods 
 
 
The following molecular biology methods were performed according to the standard 
protocols decribed by Sambrook, and Russel (2001) and Ausubel et al. (1993): Plasmid-
minipreparation from E. coli (STET-Minipreparation), phenol extraction, ethanol 
precipitation and agarose gelelectrophoresis. Corresponding kits were used for other 
standard molecular biology method according to manufacturer’s instructions: JetStar 
(Genomed, Bad Oeyenhausen) for plasmid-maxipreparation, Qiaex II Gel Extraction Kit 
(Qiagen GmbH, Hilden, Germany) for DNA fragment isolation from agarose gel and 
PCR-Purification-Kit (Qiagen GmbH, Hilden, Germany) for PCR fragment purification 
from agarose gel. 
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2.2.1. Molecular biology methods 
 
 
2.2.1.1. Culturing and storage of bacteria 
 
Escherichia coli strains XL-1 Blue MRF’ and SOLR were cultured in a bacteria incubator 
or, as liquid culture, in a bacteria shaker (New Brunswick Scientific Co., Edison, USA) at 
37 °C. Appropriate concentrations of antibiotics (ampicilin 100 µg/ml, tetracycline 12,5 
µg/ml, and kanamycin 50µg/ml) were used for bacteria culturing. For long-term storage of 
bacteria, 1 ml of a dense bacteria culture (OD 1,0) was centrifuged at 4000 rpm for 10 
min, the bacteria resuspended in 1ml of storage medium (10% (w/v) glycerin in LB-
medium), transferred in cryotubes (Nunc, Wiesbaden) and frozen at – 80 °C. 
 
2.2.1.2. RNA isolation, cDNA preparation and reverse transcription polymerase     
 chain reaction (RT-PCR) 
 
Total RNA was isolated from 1x107 cells using RNeasy-Mini-Kit (Quiagen GmBH, 
Hilden) according to manufacturer’s instruction. Purified RNA was resuspended in 
RNase-free water and aliquots were stored at –80 ˚C. cDNA was prepared from RNA by 
using MuMLV reverse transcriptase (New England Biolabs, Schwalbach) and Taq 
Polymerase (Promega, Heidelberg) accoding to the guidelines of the manufacturers in a 
total volume of 20 µl. For 3 µg total RNA 1 µl oligo (dT) (Roche, Mannheim) and H2O to 
a volume of 14 µl were added. Mixture was heated to 70°C for 10 min and chilled on ice 
for 30 sec. The following components were added:  
 
4 µl 5x Reverse transcriptase buffer  
1 µl Reverse transcriptase 
1 µl 10 mM dNTP mix  
 
The reaction was incubated at 37˚C for 1 hour. The dNTP mix was purchased from 
Amersham Pharmacia, USA. All other reagents used were from Promega, Heidelberg. 
Each PCR reaction was set up in a total reaction volume of 50 µl using 3 µl of RT product 
and 1 U of Taq DNA polymerase (Promega, Heidelberg). After initial denaturation at 
95°C for 5 min, 40 cycles were performed. Each cycle consisted of a denaturation step at 
95°C (1 min), followed by a primer annealing step (1 min) at the annealing temperature 
(AT) between 56 and 62 °C depending on the primer pairs used, and an extension step at  
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72°C (2 min). Primer pairs were designed to amplify sequences specific for cDNAs of 
identified antigens. After size separation by gel electrophoresis (1% agarose in TAE 
buffer), PCR products were purified using Qiaex II Gel Extraction Kit (Qiagen, Hilden). 
 
2.2.1.3. Separation of DNA fragments by agarose gel electrophoresis  
 
Separation of DNA fragments was performed on 0.8-1.2% agarose gels with 0.4 µg/ml 
ethidium bromide in 1 x TAE at 5-10 V/cm. DNA samples were mixed with 6x 
concentrated gel loading buffer (0,25% (w/v) bromophenol blue, 0,25% (w/v) xylene 
cyanol, 30% 0,25% (v/v) glycerol) and loaded into the gel slots. Electrophoresis was 
performed in the horizontal position with 1x TAE running buffer. 1 Kb DNA Ladder 
(MBI Fermentas) was used as size standard. For the isolation of DNA fragments from 
agarose gels, DNA was run on an agarose gel, the desired fragments cut from the gel and 
DNA isolated using a Qiaex II Gel Extraction Kit (Qiagen, Hilden) according to 
manufacturer’s instructions. 
  
2.2.1.4. Phenol-chloroform extraction and precipitation of DNA  
 
To remove contaminants from DNA, an equal volume of a mixture of phenol, chloroform 
and isoamyl alcohol (proportions 25/24/1) was added to the DNA solution to be cleaned. 
The mixture was centrifuged for 10 min at 13000 g to separate the phases. The aquous 
upper phase was taken and DNA precipitated by the addition of 2 vol. 100% ethanol and 
0.1 vol. 3 M sodium acetate. After centrifugation at 13000 g the pellet was washed in 70% 
ethanol, dried and dissolved in H2O. DNA concentration was measured by UV-
spectrophotometer.  
 
2.2.1.5. DNA restriction 
 
2-4 U of the desired restriction enzymes were added to 1 µg of DNA in the appropriate 
restriction buffer. The total volume of digestion was 10 x the volume of enzyme added, as 
glycerol in the enzyme storage buffer may inhibit the reaction. The restriction mix was 
incubated for 2 h at 37°C.  
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2.2.1.6. Ligation  
 
DNA fragments with compatible ends were ligated with T4 DNA ligase. The amount of 
insert used was 3-6 times that of dephosphorylated vector. 1 U enzyme in 20 µl ligation 
solution (Boehringer, Mannheim) was added to 200 ng DNA and the reaction was 
incubated overnight at 16°C.  
 
2.2.1.7. Mini- and Maxi-preparation of plasmid DNA 
 
A single bacterial colony was inoculated into 5 ml LB medium containing the appropriate 
antibiotic and incubated overnight in a shaker at 37°C. The overnight culture was then 
spun down at 3000 rpm, the supernatant discarded and the bacterial pellet was 
resuspended in 100 µl of solution 1. The cells were lysed by the addition of 100 µl of 
solution 2 and incubated at RT for 5 min. The suspension was neutralized with 100 µl of 
solution 3 and centrifuged 10 min. at 13000 g.  The supernatant was transferred into new 
tube and 700 µl of 100% ethanol was added for DNA precipitation and the solution was 
centrifuged for 20 min at 13000g. Supernatant was poured off and DNA was air dried for 
15 min. DNA was resuspend in 100 µl H2O. 
 
Solution 1: 50 mM Tris-HCl (pH 8) ; 10 mM EDTA ; 100 µg/ml RNase A  
Solution 2: 200 mM NaOH ; 1 % SDS (w/v)  
Solution 3: 3 M potassium acetate, pH 5.5 
 
Large amounts of plasmid DNA were obtained from 500 ml LB overnight culture using 
JetStar (Genomed, Bad Oeynhausen), according to manufacturer’s instruction.  
 
2.2.2. SEREX methods 
 
2.2.2.1. Construction of the cDNA library 
 
PBL were obtained 3,5 months after BMT and frozen in liquid nitrogen. PBL were 
stimulated four times in T cell medium containing 0,25 µg/ml PHA (Sigma Chemie, 
München) in order to expand T cells. Total RNA was isolated by the phenol/chloroform 
method. Poly (A)+RNA was isolated using an mRNA isolation kit (Stratagene, La Jolla, 
USA). 5 µg mRNA was used for cDNA library construction, with the help of the ZAP 
express cDNA synthesis kit and Gigapack III Gold cloning kit (Stratagene, La Jolla, 
USA). Briefly, first-strand synthesis was performed using an oligo(dT) primer with an 
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internal XhoI site, 5-methyl-dCTP, dNTPs, and Moloney murine leukemia virus reverse 
transcriptase (MMLV-RT). After second-strand synthesis, EcoRI adapters were ligated to 
the cDNA and digested with XhoI. Sepharose CL-2B gel filtration was performed for size 
fractionation of the cDNA samples. The fractionated cDNA was ligated into the ZAP 
express vector. The cDNA expression library was constructed, packaged and used to infect 
Escherichia coli (E.coli) XL-1 Blue MRF’ according to instructions to the λZAPII cDNA 
Gold cloning kit (Stratagene, La Jolla, USA), resulting in more than 1,2 x 106 primary 
recombinants.  To obtain a stable quantity of a high-titer stock of phages, the library was 
amplified. 
 
2.2.2.2. Preadsorption of sera  
 
Sera from a patient undergoing allogeneic BMT was obtained after BMT and stored at -
80°C. To remove antibodies reactive with antigens related to the vector system, each 
serum was preadsorbed to XL-1 and to non-recombinant λZAPII phage particles by the 
following procedure: Preadsorption columns were prepared by using glutaraldehyde-
activated affinity adsorbens (Roche Diagnostics, Mannheim) and XL-1 either sonicated or 
lysed by λ-phage infection. Preadsorption nitrocellulose membranes were prepared as 
plaque lifts from XL-1 cultures lytically infected with λ-phages and grown on Luria-
Bertani (LB) agar plates. For preadsorption, 2 ml of serum was diluted 1:10 with Tris-
buffered saline (TBS), incubated subsequently with column bound proteins of sonicated 
and lysed XL-1 (over night, 4°C) and then with 6 plaque lifts (3 hrs each, room 
temperature). Sera were then further diluted 1:10 in TBS (0,2% low-fat dried milk) 
stabilised by addition of 0,0125% sodium acide and thimerosale and stored at 4°C. 
2.2.2.3. Immunoscreening of cDNA libraries  
For library screening, a total of 1,2×106 recombinant clones was tested as described (Sahin 
et al., 1995) with the modification that serum was primarily diluted only 1:100 as reported 
by Scanlan et al. (Scanlan et al., 1999). Briefly, λ-phage infected XL-1 were plated on LB-
agar (3,5 × 103 plaque forming units per 15 cm plate) and expression of recombinant 
proteins induced with isopropyl β-D-thiogalactoside (IPTG). Following overnight 
incubation, proteins were transferred to nitrocellulose membranes, which were washed 
with TBS-T (TBS plus 0,5% Tween 20), blocked with 5 % low-fat dried milk in TBS and 
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then incubated with preadsorbed serum over night at room temperature. Next day, 
membranes were incubated with an alkaline phosphatase-conjugated anti-human IgG 
secondary antibody (Dianova, Hamburg) and stained with 5-bromo-4-chloro-
indolylphosphate/nitro blue tetrazolium (BCIP/NBT) substrate (Sigma–Aldrich, 
Taufkirchen). Staining membranes without prior serum exposure identified recombinants 
expressing IgG. Positive clones were picked, subcloned to monoclonality by using the 
same plaque assay procedure and stored in SM buffer. 
2.2.2.4. Single clone excision and plasmid extraction 
E. coli (XL1-Blue MRF) was infected with isolated positive clone and ExAssist helper 
phages (1 million PFU, Stratagene, La Jolla, USA). After cell lysis and removal of cell 
debris, solutions containing the excised pBluescript phagemid vector packaged as 
filamentous phage particles were incubated with E. coli (SOLR strain). This allows only 
the excised phagemid to replicate in the host. The cell mixture was plated on LB-
kanamycin agar plates, and single clones were picked and grown in kanamycin-containing 
LB medium. Plasmid DNA was purified over JetStar columns (Genomed, Bad 
Oeynhausen). 
 
2.2.2.5. Sequencing and homology search 
Monoclonal plasmid DNA was sequenced with T3 (5’ AATTAACCCTCACTAAAGGG 
3’) and T7 (5’ GTAATACGACTCACTATAGGGC 3’) primers. After sequencing of the 
cDNA inserts, GenBank databases ( )http://www.ncbi.nlm.nih.gov/  were screened for 
homologies. Corresponding genomic DNA sequences were analysed using the Internet 
address http://searchlauncher.bcm.tmc.edu/seq-search/gene-search.html (programs: 
FGENES, FEXH, HSPL, HEXON, TSSG, TSSW and NNP). Open reading frames were 
predicted by computer programs (Clone Menager 6, Genetool).  
2.2.3. Cell biology methods 
2.2.3.1. Patient/donor pair  
A pediatric patient with β-thalassemia major (BM recipient) and her HLA-identical sister 
(BM donor) were enrolled in this study which had been approved by the ethical review 
board of the Technical University of Munich. HLA-identity was demonstrated by genetic 
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and immunological methods in the National reference laboratory for tissue typing (Prof. 
Dr. med. E. Albert, Labor für Immungenetik, Poliklinik der Ludwig-Maximilians 
Universität, München). The conditioning regimen included busulfan, cyclophosphamide 
and antithymocyte globulin and was well tolerated. For prophylaxis of GvHD, the patient 
received cyclosporine and methotrexate. 5 x 108/kg unfractionated mononuclear cells of 
donor BM were infused. Three weeks after BMT, the patient developed mild GvHD in 
liver, skin and gut. Immunosuppressive therapy was given for three months after BMT. 
Blood samples were collected from the patient one month before BMT as well as three 
and three and a half months after BMT (d90 and d100). A blood sample from the donor 
was obtained at the time of transplantation. Chimerism analysis at any time after BMT 
proved that all PBL collected from the patient after BMT were of donor type (PD Dr. med. 
P. Bader, MRD/Chimerismuslabor, Abteilung I: Pädiatrische Hämatologie/Onkologie, 
Universität Tübingen). 
2.2.3.2. Retrieval and storage of the cells 
PBL were obtained in syringes and upon arrival, immediately processed. Density gradient 
centrifugation was performed using Ficoll-Paque. For this separation, 20 ml of PBL were 
transferred into 50 ml Falcon tubes and under layed with 14 ml Ficoll-Paque. PBL were 
centrifuged for 30 min, 2000 rpm, 4 ˚C. The same procedure was used for the preparation 
of feeder cells from “Buffy Coats”. After separation, leukocytes were collected from the 
interphase, transferred to a new tube, filled up with RPMI-1640 to 50 ml and centrifuged 
at 1500 rpm for 10 min. This wash step was repeated, then cells were resuspended in an 
appropriate volume of media and further cultivated in 24-well plates. Cells were expanded 
and aliquots frozen and stored in liquid nitrogen. Cells were frozen in fetal calf serum 
supplemented with 10% DMSO. When needed, frozen cells were thawed rapidly in a 37 
˚C water bath, resuspended in appropriate medium, and further cultivated in appropriate 
cell culture plates or flasks. 
2.2.3.3. General cell culture conditions and maintenance of cell lines 
All mediums were stored at 4 ˚C for no longer than three months, and were used within 
two weeks following addition of serum. Serum was stored at -20 ˚C for no longer than six 
months. Supplements were kept at 4 ˚C. Cell manipulations were performed in a 
biological containment cabinet (hood) using autoclaved or plastic pipets with cotton plugs 
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and strict aseptic technique. The cells were incubated in an atmosphere of 5% CO2 and at 
a temperature of 37 ˚C. Cells cultures were refed with fresh growth medium every 3 to 5 
days. Cultures were kept growing only when they were required for experimentation. Cells 
were ordinarily expended and refrozen to maintain a frozen inventory. Thawed cells were 
treated for two weeks with mycoplasma removal agent to avoid mycoplasma 
contamination. T cell lines and clones were grown in the same tissue culture conditions in 
24-, 48-, or 96 well plates in T cell medium (RPMI 1640 supplemented with 10% heat-
inactivated human serum, 2 mM L-glutamine, 100 U/ml penicillin und 0,1 mg/ml 
streptomycin and HEPES buffer (10mM)). 
2.2.3.4. Generation of Epstein-Barr virus (EBV)-transformed B cell lines (LCL)  
Several LCLs were generated during this work including LCL patient and LCL donor, and 
from 17 members of one family that shares all HLA class II alleles with the patient/donor 
pair. In all cases, EBV-transformed B cells were obtained by incubating PBL (1x106) from 
each donor with supernatant from EBV-producing B95-8 Marmoset cells, cyclosporin A 
1µl (100 µg/ml solution), and feeder cells (1x 104 Wi38 human fibroblasts cell line) in 
total volume of 200 µl/well in 96-well plate. LCL lines were grown in RPMI 1640 
supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin and 
0,1 mg/ml streptomycin and 10% heat-inactivated FCS. LCLs from all individuals were 
HLA class I and II typed and used to define the HLA restriction elements.  
2.2.3.5. PHA blast generation 
PHA blasts from patient and donor were generated by culturing PBL for three days in T 
cell media (RPMI 1640 supplemented with 10% heat-inactivated human serum, 2 mM L-
glutamine, 100 U/ml penicillin und 0,1 mg/ml streptomycin and HEPES buffer (10mM)) 
containing 0,25µg/ml Phytohemagglutinine (PHA) (Abbott Murex, Wiesbaden). After 
three days the medium was removed and PHA blasts were further cultured in T cell 
medium with IL-2. PHA blasts were used as APC in ELISPOT assay and for the isolation 
of RNA. 
2.2.3.6. Generation of mHA-specific T cell lines 
Lymphocytes were purified from PBL obtained from the patient three and half months 
after BMT using Ficoll-Hypaque (Amersham Bioscience, Uppsala, Schweden) density 
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gradient centrifugation. T cell lines specific for mHA were generated in 24-well plates 
(Falcon, MultiwellTM, Becton Dickinson/Pharmingen, Heidelberg) by stimulating 1x106 
lymphocytes obtained after BMT with 1x106 γ-irradiated (80Gy) LCL patient in a total 
volume of 2 ml/well. Stimulation was performed in T cell medium. After 24 hours 10 
U/ml IL-2 was added. After each stimulation 20U/ml IL-2 were added 24 hours later. 
After three rounds of stimulation reactivity against LCL obtained from PBL before BMT 
was measured in GM-CSF release assay and used for the generation of mHA-specific T 
cell clones.  
2.2.3.7. Generation of mHA-specific T cell clones 
T cell lines with specificity for LCL patient were cloned by limiting dilution in 96-well 
round-bottom plates (Falcon, MicrotestTM, Becton Dickinson/Pharmingen, Heidelberg). 
Each well received 1x104 γ-irradiated (80 Gy) LCL patient, 1x105 γ-irradiated (40 Gy) 
feeder cells (mixture of three PBLs obtained from unrelated donors) and 200 µl T cell 
medium containing 20 U/ml IL-2 and 0,25µg/ml PHA and T cells from previously 
generated mHA-specific T cell lines. Three independent dilutions were made containing 
10, 3, and 1 responder T cell from mHA-specific T cell lines per well. Three days later 
medium was removed and fresh T cell medium containing 20 U/ml IL-2 was added. After 
10 days the cultures were restimulated. Wells exhibiting T cell growth were identified by 
microscopy, and transferred into 48-well plates for further cultivation. All further 
stimulations were performed in the same fashion.  
2.2.3.8. Determination of IL-2, IL-4 and GM-CSF by cytokine ELISA and antibody 
blocking studies  
 
Specific recognition assays in this work were performed by measuring cytokine release 
into the media after specific recognition of target cells by T cells. The measurement of 
cytokines in T lymphocyte culture supernatant was performed by ELISA. The plates were 
coated with an anti-cytokine antibody, and bound cytokines were revealed by a second, 
biotinylated anti-cytokine antibody. Assays were performed according to manufacturer’s 
instructions (kits from R & D Systems and Endogen). Briefly, ELISA plates (StripwellTM 
Plate, Costar, USA) were coated overnight at 37°C with 100 µl/well capture mouse anti-
human cytokine antibody in PBS. Plates were washed three times with PBS/0.05% 
Tween-20, blocked with 300 µl/well PBS supplemented with 1% bovine serum albumin 
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(BSA) (ICN Biomedicals Inc., Ohio, USA), 5% sucrose and 0,02% Na-acide for 1 hour at 
room temperature, and washed three times with PBS/0.05% Tween-20. 100 µl/well of the 
samples were added to ELISA plates and incubated overnight. Next day, plates were 
washed three times and incubated for two hours with detection antibody (biotinylated 
mouse anti-human cytokine). The plates were then washed three times and streptavidine 
conjugated to horseradish-peroxidase was added and incubated in the dark for 20 min. 
After 3 washes, 100 µL/well substrate solution (1:1 colour reagent A (H2O2) and colour 
reagent B (tetrametilbenzidine), R&D System, USA) was added and incubated at room 
temperature for 20 minutes. After addition of 50 µl/well stop solution (2N H2SO4), 
absorption was measured at 450 nm using a reference wavelength of 690 nm. The 
colorimetric measurement was performed using an ELISA Reader Tecan (Tecan, 
Crailsheim) using Xread Plus software for quantification (Tecan, Crailsheim). Some 
assays were performed by preincubating the target cells for 30 min at 37˚C in the presence 
of 25 µg blocking antibodies (monoclonal anti-human HLA class I antigene, clone 
W6/32), (monoclonal anti-human HLA-DR, L243) per 105 cells in a total volume of 200 
µl/well. Cytokine secretion by T-cell lines and clones was assessed after 1x105 effector 
cells were cultured in 96-well microplates with 1x105 stimulator cells in 200 µl of T-cell 
medium. After 24-h incubation, 100 µl/well supernatant was harvested, and the release of 
cytokine was determined using an ELISA kit. 
 
2.2.3.9. IFN-γ ELISPOT 
 
The frequency of T lymphocytes specific for antigens 10, 10-2 and 21 in the T cell lines 
generated from PBL post BMT was determined with an IFN-γ-specific ELISPOT assay. 
Assays were performed in 96-well nitrocellulose-lined microtiter plates (Millipore, Mana 
S45, Germany) coated with anti-IFN-γ mAb 1-D1K (Mabtech, Stockholm, Sweden) 
overnight at 4°C. The plates were washed three times with PBS, and then blocked with 
RPMI supplemented with L-glutamine, penicillin, and 10% heat-inactivated pooled human 
AB serum for 1 h.  The plates were again washed three times with PBS and T cell lines 
were tested in the assay as follows: Freshly prepared PHA blast cells were γ-irradiated 
(40Gy) and plated at 1x105 cells/well in serum-free medium and 1µl/well peptides 
(1mg/ml solution) was added directly to Ab-coated ELISPOT plates in a volume of 100 
µl. 1x105 T cells were added to each well and incubated overnight at 37°C. The final 
volume in each well in the ELISPOT plate was 200 µl. After 24 h the cells were removed 
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by washing three times with PBS and four times with PBS containing 0.05% Tween 
(PBST). Next, 100 µl of 1 µg/ml of the biotinylated anti-IFN-γ mAb 7-B6-1 biotin 
(Mabtech, Stockholm, Sweden) were added. After 3 h of incubation, plates were washed 
six times more and a 1:1000 dilution of Sigma ExtraVidin peroxidase conjugate (Sigma–
Aldrich, Taufkirchen) was added to the wells and the plates incubated at room temperature 
for a further 2 h. Then, wells were again washed 6 times and 100 µl of Sigma Fast DAB 
(3,3’-diamino benzidine, urea H2O2 in 10 ml deionized H2O) filtrated solution was added. 
After 30 min, the colorimetric reaction was terminated by washing with tap water and 
plates were air dried. Next day the plates were analysed using light microscopy. The 
frequency of Ag-specific cells was calculated as the number of spots per well.  
 
2.2.3.10. Flow cytometric analysis of mHA-specific T cell clones 
 
T cell lines and clones were analyzed by two-color flow cytometry for expression of CD4, 
CD8, CD16, CD45RO, CD62L, HLA class I, HLA-DR, TCRαβ, TCRγδ using 
phycoerythrin (PE)-conjugated anti-CD4 and fluorescein isothiocyanate (FITC)-
conjugated anti-CD8 antibodies. All other antibodies were unlabeled and detected using 
(FITC)-conjugated mouse anti human IgG secondary antibody (Becton 
Dickinson/Pharmingen, Heidelberg). Briefly, about 3x105 cells were centrifuged (5min, 
500xg, 4˚C), in 100µl FACS buffer (PBS, 2% FCS), resuspended and incubated 30 min on 
ice with primary antibodies in the dark. After washing three times in 1 ml FACS buffer, 
cells were incubated 20 min on ice with FITC-conjugated secondary antibody. Cells were 
washed three times with 1 ml of FACS buffer and resuspended in 400 µl FACS buffer 
with 2 µl/ml propidium iodide. Analysis was performed on a FACScan flow cytometer 
with CellQuest software (Becton Dickinson) and WinMDI 2.8 (J. Trotter; Scripps 
Research Institute, LA Jolla, CA; http:/facs.scripps.edu/). 
 
2.2.3.11. Isolation of peptide specific T cells: MACS Cytokine Secretion assay  
 
In this study, IFN-γ secreting cells were isolated from the T cell line generated from PBL 
obtained from the patient after BMT. Three fractions of the T cell lines each containing 
5x106 cells were incubated for 16 hours (at 37˚C, 5% CO2) with 10µl of peptides 10, 10-2 
and 21 (1µg/µl solution). After 16 hours cells were spun down (1500 rpm, 10 min, 4˚C), 
washed with 10 ml of cold buffer and again centrifuged at 1500 rpm for 10 min at 4˚C. 
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Subsequently, the cell pellet was resuspended in 80 µl of cold buffer, 20 µl of IFN-γ catch 
reagent (20 µl/107 total cells) was added, mixed, and incubated for 5 min on ice. After 
incubation, 10 ml warm medium (37˚C) was added to dilute the cells, then incubated for 
45 min (37˚C, 5% CO2), and mixed every 5 min. The samples were centrifuged at 1500 
rpm for 10 min at 4˚C, the supernatant was removed completely, and the cells were 
washed twice. The cell pellet was resuspended in 80 µl of cold buffer, 20 µl of IFN-γ 
detection antibody (PE) was added, mixed, and incubated for 10 min on ice. Cells were 
washed with 10 ml cold buffer two times, centrifuged at 1500 rpm for 10 min at 4˚C. For 
magnetic labeling, the cell pellet was resuspended in 80 µl of cold buffer, then 20 µl of 
anti-PE microbeads were added, mixed, and incubated for 15 min at 4˚C followed by 
washing the cells two times with cold buffer (1500rpm, 10 min, 40C) and removing the 
supernatant completely. The cells were resuspended in 1 ml of cold buffer. For magnetic 
separation, LS columns were put in the magnetic field of the MACS separator and rinsed 3 
times with 3 ml of cold buffer. Magnetically labeled cells were loaded onto the columns. 
The columns were washed with 3 x 1 ml cold buffer, and the effluent was collected as 
negative fraction. Three ml of cold buffer was pipetted on top of the column. Using a 
plunger, the retained cells were pushed out from the column and harvested by 
centrifugation. 
 
Cold buffer:  PBS pH 7.2, containing 0.5% bovine serum albumin (BSA) and 2 mM 
EDTA,  4 ˚C  
 
Medium:  RPMI 1640 containing 5% human serum
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3.  Results 
 
 
3.1. Strategy for mHA identification 
 
 
It has been shown that CD4+ T cells play an important role in GvHD (van Els et 
al., 1989; van Els et al., 1990; Shenoy et al., 1998) and GvL responses (Faber et al., 1995; 
Alyea et al., 1998; Alyea et al., 2001) after allogeneic BMT. Thus, for separating GvL 
from GvHD responses, it is important to know the antigens recognized by CD4+ T cells. 
However, current methods for the identification of antigens presented on MHC class II are 
complicated and time-consuming procedures. It is known that B cells require T cell help 
for switching their isotype and the production of highly specific antibodies. Therefore, two 
approaches for the identification of mHA presented on MHC class II should be taken in 
parallel (Fig.3). First, mHA-specific CD4+ T cell clones involved in the cellular immune 
response after BMT should be isolated. Second, the targets of antibody response after 
BMT should be identified with the SEREX method. Polymorphisms should be identified 
by comparing the sequences of the genes encoding the antigens in patient and donor 
(before and after BMT). Polymorphic antigens would be candidate mHAs. These antigens 
should then be tested in a recognition assay with mHA-specific T cell clones isolated from 
the patient after BMT. This strategy should give an answer to the question, whether the 
humoral and cellular immune responses are directed against the same or different antigens. 
The specific recognition of these candidate mHAs by the CD4+ mHA-specific T cell 
clones would provide evidence that these antigens truly represent mHAs, and that the 
serological approach can be used to identify MHC class II-restricted antigens recognized 
by CD4+ T cell clones.The role of these antigens in the immune response after BMT 
should additionally be examined by measuring the frequency of the T cells specific for 
these antigens before and after BMT.  
 
 
3.2. Cellular immune response after BMT 
 
3.2.1. Generation of mHA-specific T cell lines 
The pediatric patient analyzed in this work suffered from β-thalassemia and 
received BM from an HLA-identical sister. Approximately 30 days post BMT the patient 
developed mild symptoms of GvHD. Peripheral blood leukocytes (PBL) were collected 
from the patient before, and one hundred days after BMT. Since it was not possible to 
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collect enough material to generate dendritic cells (DC), LCL were used as antigen 
presenting cells (APC). 
 
 
 
Patient
 
HLA-identical BMT
cellular immune responsehumoral immune response 
generation of mHA-specific 
 T cell lines antigen identification
detection of polymorphism
in donor/recipient pair 
generation of mHA-specific 
CD4+ T cell clones 
recognition 
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T cell precursor 
frequency pre/post BMT
 
 
 
Fig.3 
Strategy for mHA identification. In a patient receiving HLA-identical BM, both 
the cellular and the humoral immune response after BMT should be assessed in parallel. 
The targets of the humoral immune response should be identified, and in order to detect 
any polymorphisms in these antigens, their sequences should be compared between patient 
and donor. mHA-specific CD4+ T cells lines should be generated from PBL of the patient 
after BMT, and cloned by limiting dilution. The antigens identified as the targets of 
antibody response should then be tested in a recognition assay, to determine whether the 
mHA-specific CD4+ T cell clones recognize these or different antigens. Furthermore, the 
precursor frequency of the T cells recognizing the targets of the humoral immune response 
should be determined before and after BMT. 
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The PBL collected before BMT were used to generate a LCL of recipient type and 
therefore designated “LCL patient”. Chimerism analysis at different time points after 
BMT revealed that all PBL were derived from the BM donor. Thus, the PBL collected 
from the patient after BMT are of donor origin, and the LCL generated from these PBL 
are designated “LCL donor”. In order to generate mHA-specific T cell lines, T cells from 
PBL taken 100 days after BMT were stimulated with irradiated LCL patient. In a 24-well 
plate, 1 x 106 PBL obtained from the patient after BMT were stimulated with 1 x 106 
irradiated LCL patient/well in 2 ml of T cell media. After 24 hours, 10 U/ml IL-2 was 
added. Depending on cell growth, cells were split and after ten days restimulated in an 
identical fashion. The specificity of the three T cell lines generated, designated I, II and 
III, was tested by comparing the reactivity of T cell line against LCL patient and LCL 
donor in a GM-CSF release assay (Fig.4). Because EBV-transformed B cells present self 
and EBV-antigens on MHC class I and II molecules, mHA-specific as well as EBV- or 
autoantigen-specific T cells were generated.  
Specificity of T cell line after three stimulations
0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
LCL patient LCL donor T cells + media
OD 450 nm
 
Fig.4 
Specific T cell recognition of a representative T cell line (I) generated from PBL of 
the patient after BMT. Upon recognition of antigen, T helper cells secrete cytokines into 
the cell culture supernatant. The amount of cytokine in the supernatant can be quantified 
by a sandwich ELISA-based color reaction, which is measured at 450 nm (OD 450 nm). 
Release of granulocyte-macrophage colony-stimulating factor (GM-CSF) was measured in 
this work. PBL obtained from the patient three and a half months after BMT were 
stimulated three times with LCL patient. mHA specificity of the generated T cell line was 
tested by comparing reactivity of the line against LCL patient and LCL donor. 
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The reactivity of T cells against either group of antigens was assessed by testing 
the T cells against LCL patient and LCL donor. Several mHA-specific T cell lines, that 
preferentially recognize antigens expressed on LCL patient but not on LCL donor, were 
generated by this protocol.  
 
3.2.2. Generation of mHA-specific T cell clones 
 mHA-specific T cell clones were isolated from these mHA-specific T cell lines by 
limiting dilution cloning. Three different T cell lines, stimulated three, four or six times 
with LCL patient were used. Clones obtained from these lines are denoted by the appendix 
I, II and III. Limiting dilution cloning was performed in 96-well round-bottom plates by 
seeding 1, 3 or 10 T cells per well in 200µl T cell medium supplemented per ml with 250 
ng PHA, 20U IL-2, 5x105 irradiated feeder cells and 5x103 irradiated LCL patient.  
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Fig. 5   
Recognition pattern of representative T cell clones. The generated T cell clones 
showed three types of specificities when tested for recognition of LCL patient and LCL 
donor. Examples of three clones representing these three recognition patterns are shown. 
Clone H4 III reacts against LCL patient and LCL donor and therefore recognizes an EBV- 
or autoantigen. The specificity of clone E4 III is unknown, because neither LCL patient 
nor LCL donor were recognized. Clone B3 II shows the typical recognition pattern for 
mHA-specific clones. This clone recognizes LCL patient but not LCL donor.  
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Sixty-seven clones were isolated, expanded, and their specificity tested (Fig.5). T cell 
clones with three different types of specificities were isolated. The specificity of the first  
group is directed against EBV- or auto-antigens because antigens presented on both LCLs 
were recognized. T cell clones in the second group neither responded to LCL patient nor  
LCL donor. The specificity of these clones is unknown. The recognition pattern of the 
third group is characteristic for clones with specificity for mHA. LCL patient were highly 
recognized whereas LCL donor were not. The majority of the T cell clones were mHA-
specific.  
These mHA-specific T cell clones were further characterized and the phenotype 
determined. Antibodies to the cell surface molecules CD4 and CD8 were used in 
fluorescence-activating cell sorting (FACS) analysis to determine the T cell subtype of the 
clones. As illustrated in the Figure 6, mHA-specific T cell clones generated from all three 
T cell lines (I, II and III) were CD4+ and CD8-. Thus, only CD4+ but no CD8+ T cell 
clones were established under these in vitro culture conditions.  
 
3.2.3. Determination of the restriction element 
 
CD4+ T cells recognize antigenic peptides bound to the binding groove of MHC 
class II molecules. As every individual inherits three different HLA class II molecules 
from mother and father, usually six different MHC class II molecules are expressed. 
Depending on the HLA genotype, up to two additional HLA-DRβ chaines can be 
expressed. To determine which of these MHC class II molecules presented the antigen to 
the CD4+ T cell clones, a panel of allogeneic LCL, which share one or more HLA 
molecules with the patient, was tested. Because LCLs have to express the mHA in 
addition to the restricting MHC class II molecule, the determination of the restriction 
molecules for mHA-specific CD4+ T cell clones is complicated. Therefore, a large panel 
of allogeneic LCLs that share one or more HLA class II molecules with the patient/donor 
pair was tested for recognition by the mHA-specific T cell clones. In the same experiment, 
blocking studies were performed using antibodies directed against HLA class I (W6/32) 
(anti-HLA A, B, and C) and HLA class II (L243) (anti-HLA-DR) molecules. A 
representative example of this analysis is shown in the Figure 7A. Recognition of 
autologous LCL by clone E8 II was blocked with an antibody against HLA-DR but not 
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with an antibody against HLA class I molecules, showing that this clone is HLA-DR 
restricted. 
clone D5-2I 
   
clone B5II 
   
clone B10III 
   
 
 
Fig. 6 
FACS analysis of mHA-specific T cell clones. Representative examples of three 
clones D5-2 I, B5 II and B10 III established from three T cell lines (I, II and III) are 
shown. All isolated mHA-specific T cell clones are CD4+ and CD8-. Control represents 
staining with propidium-iodide for dead cells.  
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Fig. 7 
A) Blocking experiment performed with clone E8 II. In order to determine the 
MHC class II restriction element for clone E8 II, blocking antibodies were used in the 
recognition assay. Recognition of autologous LCL could be blocked with an anti-HLA-DR 
antibody but not with an anti-HLA class I antibody, indicating that this clone is HLA-DR 
restricted.  
B) Recognition of allogeneic LCLs by mHA-specific T cell clone E8 II. A panel of 
allogeneic LCLs established from unrelated donors which share one or more HLA class II 
molecules with the patient were used in a cytokine secretion assay. Only one LCL that 
shares HLA-DR and DQ with the patient/donor pair was recognized, therefore it was not 
possible to determine the restriction molecule. 
 
Besides the LCL patient, only one allogeneic LCL was recognized by clone E8 II. 
The HLA class II type of this LCL was identical with the HLA type of the patient/donor 
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pair. All other LCLs share one or more HLA class II alleles with the patient/donor pair, 
but none of them was recognized, most likely because these LCLs do not express the 
mHA recognized by the T cells. 
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Fig. 8 
 
Family tree of donor GB-1-C3. In order to identify the restriction elements of the 
mHA-specific CD4+ T cell clones, LCLs from seventeen members of the family from 
which LCL GB-1-C3 originated, were generated and HLA typed. GB-1-C3 shares all 
tested HLA class II alleles (DR, DQ) with the patient/donor pair and expresses the mHA 
recognized by T cells. For reasons of lucidity, numbers are given instead of names for 
each of the generated LCLs. The HLA genotypes for HLA-DR and HLA-DQ alleles are 
given below the symbol for the gender of each family member. 
 
 
Because only LCL GB-1-C3 was recognized, it was not possible to determine the 
HLA restriction molecule. These results indicated that the mHA recognized by the T cell 
clone is expressed in a minority of the LCLs only. Similar results were obtained with other 
T cell clones. Therefore, instead of generating and testing a larger number of LCL from 
unrelated donors, several family members of the donor from whom LCL GB-1-C3 
originated were analyzed. Within this family, the mHA recognized by the T cells is 
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expressed. In addition, LCL GB-1-C3 shares all tested HLA class II alleles with patient, 
implying that other family members may share at least one or more HLA class II alleles 
with the patient.  
It was a lucky case that the donor, from which LCL GB-1-C3 had been generated, 
is a member of a big family from which PBLs were available. LCLs from 17 family 
members were generated and HLA typed (Fig. 8). All mHA-specific T cell clones were 
then tested in a GM-CSF release assay for specific recognition of these 17 LCLs including 
LCL patient and LCL donor as control. Four recognition patterns were observed (Fig. 9). 
Most of the T cell clones showed a pattern of recognition as exemplified for clone E10 III. 
This clone recognizes LCLs 9, 10, 14, 15, 16 and 17. All these LCLs express DR11 and 
DQ03 alleles. Blocking experiments had shown that this clone is DR and not DQ 
restricted. Therefore, the restriction element for this clone is DR11. Because most of the 
generated clones showed the same recognition pattern as clone E10 III, the antigen 
recognized by this clone probably is immunodominant. LCLs 1, 4 and 12 were not 
recognized by these clones, although they are HLA-DR11 positive. Thus, these LCLs do 
not express the mHA recognized by this clone. This pattern of recognition further 
confirms that the clones are mHA-specific. The inheritance of mHAs follow the 
Mendelian rules (den Hann et al., 1998), and therefore one can expect that the specific T 
cell recognition of the LCLs generated from one family will also follow the expression of 
the specific allele through this family. This prediction did hold true for the mHAs 
recognized by clones E10 III and C3 III. Clone E10 III recognizes LCLs from the father 
and a daughter (LCLs 9 and 16), but LCLs from the mother and the two other daughters 
are not recognized (LCLs 1, 7 and 12). In contrast, clone C3 III recognizes LCLs from the 
father (LCL 16) and all three daughters (LCLs 1, 9, and 12), showing that the antigen 
recognized by this clone is transmitted from the father to all daughters. The antigens 
recognized by the T cells are not sex chromosome encoded, because LCLs generated from 
female and male donors were equally recognized. Clone C3 III recognizes all LCLs that 
are HLA-DR11+. Although clone E10 III and C3 III both recognize an antigen presented 
on HLA-DR11, this pattern of recognition indicates that they recognize different antigens 
(Fig. 9). So far, it was not possible to determine the restriction element for clone D5-3 II. 
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Fig. 9 
mHA-specific T cell clones were tested in a GM-CSF release assays for 
recognition of LCLs generated from 17 members of one family. Based on the recognition 
patterns, four different specificities were detected. Clone E10 III recognizes LCLs 9, 10, 
14, 15, 16 and 17. This recognition pattern shows that this clone is HLA-DR11 restricted. 
LCLs 1, 4 and 12 are also HLA-DR11+, but they are not recognized probably because they 
do not express the mHA for which this clone is specific. Clone C3 III recognizes all 
DR11+ LCLs. Therefore, this T cell clone is specific for an antigen presented on HLA-
DR11. From the recognition pattern of clone D5-3 II, it was not possible to determine the 
restriction molecule. However, additional typing showed that recognized LCLs express 
HLA-DR52 and that clone is HLA-DR52 restricted. The recognized LCLs express 
different HLA class II alleles. Clone F4 II recognizes an antigen presented on HLA-DQ06. 
 
Blocking experiments indicated that the clone is HLA-DR-restricted, because recognition 
could be blocked with an antibody directed against this molecule (data not shown). 
Depending on the HLA-DRB1 allele expressed, additional HLA-DRB alleles may be 
expressed in some individuals. Therefore, additional HLA typing of HLA-DRB3, 4 and 5 
alleles has been performed. LCL patient/donor as well as most LCLs from the family 
members expresses DR52. Therefore, additional experiments showed that this clone is 
DR52 restricted. The common restriction element expressed by all LCLs recognized by 
clone F4 II is HLA-DQ06 (Fig. 9). Together with the antibody blocking results, these data 
show that this clone is HLA DQ06 restricted.  
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3.2.4. Determination of T helper cell subtype and cell surface phenotype 
 
In order to determine the T helper cell (Th) subtype of the mHA-specific T cell 
clones, cytokine secretion assays were performed. Th cells can be subdivided into Th-1 
and Th-2 cells, depending on the pattern of cytokines they secret upon stimulation. IFN-γ 
and IL-4 are regarded as typical cytokines for Th-1 and Th-2 cells, respectively. 
Therefore, secretion of these cytokines upon antigen stimulation was determined for all T 
cell clones. As shown for T cell clone E10 III, all generated clones secreted IFN-γ, but not 
IL-4, and therefore belong to Th-1 type of T helper cells (Fig.10).  
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Fig. 10 
Determination of Th subtype. IL-4 and IFN-γ release were measured after 
stimulation of clone E10 III with LCL patient, irrelevant LCL 1.11 and without 
stimulation. Secretion of IFN-γ but not IL-4 showed that this clone is of Th-1 phenotype.  
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Fig. 11 
Phenotypic analysis of the mHA-specific clone E10 III. Propidium iodide (PI) 
staining was used to exclude dead cells, and background fluorescence was determined by 
staining with secondary antibody only (AbII). Cells were tested for expression of HLA 
class I, CD4, CD8, CD16, CD45RO, CD62L, TCR α/β and TCR γ/δ. The phenotype of 
clone E10 III is typical for antigen experienced CD4+ α/β T cells. 
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In order to further characterize the mHA-specific CD4+ T cell clones, 
immunophenotype analysis was performed using fluorescence-activating cell sorting 
(FACS). Cells were stained with antibodies directed against CD4, CD8, natural killer 
(NK) cell marker CD16, memory cell marker CD45RO, CD62L (L-selectin) receptor 
involved in lymphocyte homing after activation, T cell receptor (TCR) α/β and γ/δ (Fig 
11). As exemplified by clone E10 III, all mHA-specific T cell clones are CD4+ and CD8-. 
The small peak that appears in anti-CD8 staining probably represents CD8+ cells from 
feeder cells that have been used for restimulation. The cells are negative for NK cell 
marker CD16, positive for memory marker CD45RO, and negative for CD62L. All T cells 
are TCRα/β positive and TCRγ/δ negative. 
 
 
3.3. Humoral immune response 
 
 
3.3.1. Expression library construction and antigen identification 
   
In order to identify the antigens against which the humoral immune responses after 
BMT are directed, the SEREX methodology had to be adapted. With the SEREX method 
antigens can be identified, against which high titer antibodies are present in the serum of 
the patient (Fig. 12). A cDNA expression library was constructed from the same patient 
with β-thalassemia mentioned above who received allogeneic BM from an HLA-identical 
sister. The SEREX method is based on the recognition of proteins from an expression 
library by high titer IgG antibodies present in the serum of the patient. Bound antibodies 
are detected with an alkaline phosphatase conjugated goat anti-human IgG secondary 
antibody. One of the difficulties in antigen identification is the contamination with IgG 
genes derived from B cells in the target tissue used for library construction. Secondary 
antibodies directly recognize IgG proteins expressed in E. coli. To avoid this problem and 
to identify antigens specifically expressed in hematopoietic cells, PBL from the patient 
taken before BMT were stimulated with phytohemagglutinin (PHA), which non-
specifically activates T cells and induces their proliferation. After several rounds of 
stimulation, a pure population of T cells was obtained and the mRNA isolated. This 
mRNA was reverse-transcribed into cDNA, cloned into the λ ZapII expression vector, and 
packaged into λ-phage particles. These were used to infect E.coli and recombinant protein 
production was induced with IPTG. 
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Construction of a cDNA expression library 
 
T cells before BMT mRNA cDNA  ZAPII
Immunoscreening 
Nitrocellulose + Serum after BMT       +   anti - hu IgG - Ab (AP)            λ              
cDNA 
 
Fig. 12 
Antigen identification by the SEREX method. mRNA is extracted  from the tissue 
under investigation, here from T cells, reverse-transcribed into cDNA and ligated into a λ-
phage expression vector. The recombinant vector is then packaged, and the recombinant 
lambda phages used to lytically infect E. coli. The recombinant protein expression is 
induced by IPTG, and proteins are blotted onto nitrocellulose membranes, which are then 
incubated with serum from the patient. Serum antibodies bound to recombinant proteins in 
lytic plaques can be detected with an enzyme-conjugated anti-human IgG secondary 
antibody, and the positive recombinant λ-phage can be isolated from the respective agar 
plate. After in vivo excision of recombinant Bluescript vector the cDNA encoding the 
antigen can be sequenced. 
 
A total number of 1,2 x 106 recombinant clones were screened with serum obtained three 
months post BMT. The serum was preadsorbed against λ phages proteins to reduce 
background. In the first screening, 262 positive clones were isolated. Due to the high 
number of positive clones some of them were randomly chosen, excised in vivo and 
propagated in the E.coli strain SOLR. Surprisingly, sequencing of this randomly chosen 
clones showed that most of the cDNAs encoded IgG heavy chains. It is not clear at the 
moment, whether these Ig mRNAs stem from surviving B cells or were the result of basal 
Ig heavy chain transcription in activated T cells. However, in order to test all primarily 
positive clones for direct binding of secondary antibody they were incubated with buffer 
instead of serum. Using this procedure, false positive clones can be excluded. Twenty-one 
positive clones, recognized by the serum of the patient after BMT, were included in 
further analysis. After in vivo excision and amplification of the resulting phagemide in the  
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Clone  
Accession 
number GeneBank entry 
2-1 XM_028710 Hematopoietic protein 1 (HEM-1), mRNA 
2-2 
NM_000993 
NM_005617 
Ribosomal protein L31 (RPL31), mRNA 
Ribosomal protein S14 (RPS14), mRNA 
8 
NM_001271 Chromodomain helicase DNA binding protein 2 (CHD2), 
mRNA 
10 
AK024488 
XM_029084 
BC030281 
FLJ00087, mRNA 
FLJ21438, mRNA 
FLJ21438, mRNA, splice variant  
20-1 AF346991 Mitochondrion, complete genome 
21-1 
AK026923 
AK074088 
FLJ23270, cDNA 
FLJ00159, mRNA 
22-1 AK056934 FLJ32372, cDNA 
22-2 NM_002985 Small inducible cytokine A5 (RANTES), mRNA  
22-3 AY007165 CDABP0163 (ICAP1), mRNA 
31 NM_016208 Vacuolar protein sorting 28 (VPS28), mRNA 
42-2 M62378 T cell receptor beta chain V beta region, mRNA 
64 NM_001015 Ribosomal protein S11 (RPS11), mRNA 
65-2 BC001773 Similar to ribosomal protein L34, mRNA 
69 XM_031425 Similar to KIAA1523, mRNA 
116 AK027092 FLJ23439, cDNA 
120-1 AL365277 Clone RP11-69E11, genomic DNA  
120-2 
133-2 
U13369 Ribosomal DNA  
209 X98411 Myosin-IF, partial mRNA 
216 AC006323 RP5-1151M5, genomic DNA 
233 
XM_004398 Similar to eukaryotic translation elongation factor 1 alpha 
(EEF1A1), mRNA 
 
Table 1 
cDNA clones identified by screening the λ-phage expression library. The 
expression library was derived from T cells taken from the patient before BMT, and 
screened with serum from the patient taken three months after BMT. Twenty different 
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antigens were identified. The number of the isolated clones, the GenBank accession 
numbers and the respective human GenBank entries are given in the table. 
 
SOLR E.coli strain, plasmids were extracted and all cDNA inserts characterized by 
restriction enzyme digestion and DNA sequence analysis. The size of the cDNAs varied 
from 150 base pairs to 1500 base pairs. DNA sequences were determined and aligned to 
sequences in the GenBank using BLASTN algorithm. The results from these alignments 
are summarized in the Table 1. 
 
3.3.2. Sequence analysis of the clones involved in the humoral immune response 
 
 mHAs represent products of polymorphic genes which differ between patient and 
donor. In order to identify polymorphisms in the antigens, the respective ORFs were 
amplified by PCR.  
 
Non-polymorphic genes 
Clone  GenBank entry 
2-1 Hematopoietic protein 1 (HEM-1), mRNA 
2-2 Ribosomal protein L31 (RPL31), mRNA 
Ribosomal protein S14 (RPS14), mRNA 
20-1 Mitochondrion, complete genome 
22-1 cDNA FLJ32372 , cDNA 
22-2 cDNA FLJ32372 , cDNA 
22-3 CDABP0163 (ICAP1), mRNA  
31 Vacuolar protein sorting 28 (VPS28), mRNA 
64 Ribosomal protein S11 (RPS11), mRNA 
65-2 Similar to ribosomal protein L34, mRNA 
69 Similar to KIAA1523 protein , mRNA 
120-1 RP11-69E11, genomic DNA 
120-2 
133-2 
Ribosomal DNA  
209 Myosin-IF, partial mRNA 
233 Similar to eukaryotic translation elongation factor 1 alpha  
(EEF1A1), mRNA 
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Polymorphic genes in the population but not in the donor/recipient pair 
Polymorphism Clone  ORF GenBank entry  Pos. 
Data base Donor/patient 
8 1 Chromodomain helicase 
DNA binding protein 2 
(CHD2), mRNA 
4173 TTA – L (Leu) ATA – I (Ile) 
116 1 FLJ23439, cDNA  673 GTC – V (Val) GCC – A (Ala) 
 
 
Polymorphic genes  
Polymorphism Clone  ORF GenBank entry Pos. 
Donor Patient 
21 1 FLJ23270, mRNA 
FLJ00159, mRNA 
636 GTG – V (Val) GTG – V (Val) 
CTG – L (Leu) 
FLJ00087, mRNA 
FLJ21438, mRNA,  
and splice variant 
3001 CGT – R (Arg) CGT- R (Arg) 
TGT- C (Cys) 
10 2 
FLJ00087, mRNA 792 CAC – H (His) GAC – D (Asp)  
 
 
Table 2  
Three groups of antigens identified by serological screening. The SEREX-defined 
antigens were divided into three groups, according to sequence homologies with GenBank 
entries and donor/patient PCR products. The first group represents non-polymorphic 
antigens. In the second group contains antigens that are identical between patient and 
donor, but are polymorphic compared to sequences in the GenBank. The third group 
contains antigens that are polymorphic between patient and donor. Patient and donor-
specific sequences were amplified from ORFs predicted in the indicated genes by PCR. In 
FLJ00087 mRNA two ORFs 10-1 and 10-2 were predicted. 
 
Therefore, total RNA was isolated from PHA-stimulated T cells obtained before and after 
BMT, and subjected to RT-PCR. cDNAs were sequenced, aligned to sequences in 
GenBank and compared to one another. Based on these results, the identified antigens 
could be divided into three groups. The first group represents non-polymorphic genes. 
These genes are identical between patient and donor and GanBank entries. Group two 
consist of genes which are identical between patient and donor, but are polymorphic in 
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comparison to sequences in GenBank. In the third group are genes that differ between 
patient and donor (Table 2). This group contains candidate mHAs. 
 The sequences of the genes in the first and largest group are identical between 
patient and donor and also with sequences in the GenBank. Antigen 2-1, for example, is 
identical to the hematopoietic protein 1 (HEM-1). This gene is expressed in hematopoietic 
cells only (Hromas et al., 1991). The ORF is 1842 bp long and, as reported in the 
GenBank entry, contains a polymorphism (“A”/“C”) at position 3366 (XM_028710). 
However, patient and donor both are homozygous for allele “C” at this position. The 
protein is 211 amino acids long and its function is not known. Antigen 22-3 has high 
similarity with integrin cytoplasmic domain-associated protein 1 (ICAP1) encoded by the 
gene CDABP0163. Two isoforms of ICAP1, a 200-amino acid protein (ICAP1-alpha), and 
a shorter 150-amino acid protein (ICAP1-beta), derived from alternatively spliced mRNA, 
are expressed in most cells. ICAP-1 is a phosphoprotein, binds beta-1 integrin, and plays 
an important role in integrin-dependent cell adhesion (Chang et al., 1997). The sequences 
of this gene in patient and donor are identical. Antigen 31 is a gene with high homology to 
yeast VPS 28 (vacuolar sorting protein). Human VPS 28 recognizes ubiquitin on 
ubiquitinated internalized EGF receptor and is involved in receptor sorting for 
endosomal/lysosomal degradation (Bishop et al., 2002). Antigen 69 is expressed in at least 
three different splicing variants. All three are similar with protein KIAA1523. This protein 
is ubiquitously expressed, represents a PHD zinc finger transcription factor and contains a 
region homologous to the human autoimmune regulator (AIRE) (Pitkanen and Peterson, 
2003). The gene is not polymorphic between patient and donor. Antigen 209 is 
homologous to myosin-IF, which belongs to the family of unconventional myosins. 
Antigen 233 is homologous to eukaryotic translation elongation factor 1 alpha 1 
(EEF1A1) which is widely expressed. Autoantibodies against EEF1A1 have been 
described in an autoimmune disease known as Felty’s syndrome (Ditzel et al., 2000). This 
factor is polymorphic in the population, but patient and donor are identical. Several of the 
identified antigens code for ribosomal proteins. Ribosomal proteins are polymorphic in the 
population but donor and patient express identical alleles.  
In the second group are two antigens that have one amino acid difference in 
comparison with the genes in GenBank. The cDNA derived from clone 8 is homologous 
to chromodomain helicase DNA binding protein 2 (CHD2). Four novel polymorphisms 
have been detected within the 5220 bp long ORF, but patient and donor are identical at 
these positions. Another novel polymorphism has been detected at position 4271 
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(NM_001271), but it represents a conservative exchange. The patient is homozygous, 
contains allele “T” whereas the donor is heterozygous and contains alleles “T” and “C”. 
An additional, novel polymorphism was detected at position 4173 (NM_001271) located 
within the ORF. Patient and donor are identical at this position, boths carrying allele “A”, 
while in the GenBank a sequence expressed from allele “T” is reported. This exchange 
leads to substitution of leucine to isoleucine on the protein level. Clone 116 codes for an 
unknown protein with homology to the hypothetical proteins FLJ23439. A polymorphism 
has been reported at position 987 (AK027092), but patient and donor express identical 
alleles. A novel, nonsynonymous exchange was detected at position 673 (AK027092). 
While patient and donor are identical at this position, expressing allele “C”, the Gene 
Bank entry derived from allele “T”. This exchange results in a valine to alanine amino 
acid substitution.  
3.3.3. Identification of polymorphic genes between patient and donor 
 The third and most important group contains antigens in which patient and donor 
differ. When interpreting the results of sequence analyses of donor and recipient RT-PCR 
products, one has to take into account that all genes located on autosomes are present in 
two copies, and, thus, the isolated mRNAs are a mixture of the transcription products from 
both alleles. Accordingly, the cDNA sequences obtained from donor and patient tissue 
after RT-PCR amplification of the ORFs, represent a mixture of both alleles, as well. 
cDNA sequence analyses reveal homogenous sequences when both alleles are identical, 
but mixed sequences when polymorphic sites are present. Such mixed sequences are 
recognized as two overlapping adsorption peaks in the electropherogram, as depicted for 
clone 21-1 (Fig. 13). Clone 21-1 represents one of the two antigens belonging to the third 
group of antigens, characterized by polymorphisms between patient and donor. The insert 
of clone 21-1 was about 1 kb in length and homologous to mRNA encoding the 
hypothetical protein FLJ23270. A single ORF, 783 amino acids in length, was predicted in 
the homologous mRNA. Within this ORF, two nonsynonymous exchanges were found. A 
novel polymorphism is located at position 184 (AK026923). At this site FLJ23270 mRNA 
represents allele “C” which codes for alanine (GCG), while the patient was homozygous 
for allele “T”, encoding valine (GTG). The donor is heterozygous at this position, carrying 
alleles “T/C” (not shown). However, an immune response relevant to GvL cannot be 
generated against this polymorphism, because the patient is homozygous and the donor 
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heterozygous and, thus, T cells recognizing mHA expressed from the “T” allele are 
negatively selected in the donor’s thymus.  
 
After BMT ( Donor)Before BMT (Patient) 
Sense orientation 
Antisense orientation 
 
 
Fig. 13  
Identification of a polymorphism in antigen 21-1 (pos. 636, AK0236923). 
Electropherograms in both sense and antisense orientation are shown. On the left hand 
side of the figure, the electropherogram obtained by sequencing the gene from the patient 
are shown in sense and antisense orientation. On the right hand side, the same part of the 
gene from the donor is shown in both orientations. The sequence obtained from the patient 
contains single letter code “S” (G or C) and, therefore, the patient is heterozygous and 
carries alleles “G” and “C”. At the same position, the donor carries allele “G” and 
therefore, is homozygous. This polymorphism results in an amino acid substitution of 
valine by leucine.  
 
A second novel nonsynonymous exchange, which was more important with respect 
to GvL, was found at position 636 (AK0236923) (Fig. 13). While FLJ23270 cDNA 
represents allele “G” which codes for valine (GTG) and the donor is homozygous, 
expressing the corresponding allele “G” (GTG), the patient is heterozygous, carrying the 
alleles “C/G” which encode leucine/valine (CTG/GTG). After BMT, GvH and GvL 
reactions due to recognition of patient type mHA derived from allele “C” may be elicited, 
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because this allele is not present in the donor, and donor T cells reactive against this allele 
are not deleted in the donor’s thymus.  
 
Gene FLJ23270 
cDNA Nonsynonymous exchange  
(pos. 184) 
Nonsynonymous exchange  
(pos. 636)  
LCL #4 
LCL 1.20 
LCL 1.23 
LCL 1.24 
LCL 1.26 
LCL Kun 
LCL #1 
LCL 3.3 
LCL GB 
LCL JM 
LCL #6 
LCL #7 
LCL UB 
CCCCGGCAGGYGCGGCAGTC 
CCCCGGCAGGCGCGGCAGTC 
CCCCGGCAGGCGCGGCAGTC 
CCCCGGCAGGCGCGGCAGTC 
CCCCGGCAGGTGCGGCAGTC 
CCCCGGCAGGYGCGGCAGTC 
CTACATGCTGGTGCCGGCCGC 
CTACATGCTGGTGCCGGCCGC 
CTACATGCTGGTGCCGGCCGC 
CTACATGCTGGTGCCGGCCGC 
CTACATGCTGGTGCCGGCCGC 
CTACATGCTGGTGCCGGCCGC 
CTACATGCTGGTGCCGGCCGC 
CTACATGCTGGTGCCGGCCGC 
CTACATGCTGGTGCCGGCCGC 
CTACATGCTGGTGCCGGCCGC 
CTACATGCTGSTGCCGGCCGC 
CTACATGCTGSTGCCGGCCGC 
CTACATGCTGGTGCCGGCCGC 
 
 
Table 3 
Detection of nonsynonymous polymorphisms in FLJ23270 mRNA of unrelated 
individuals. The parts of the gene containing the polymorphisms are shown. The whole 
ORF of antigen 21-1 was sequenced in six individuals. In seven additional individuals, 
only the region encompassing the polymorphism at position 636 (AK026923) was 
sequenced. Both alleles of the polymorphic at pos. 184 are highly represented within the 
population. Two individuals contain single letter code “Y” (C or T) and therefore, are 
heterozygous; three are homozygous for allele “C” and one is homozygous for allele “T”. 
Only two LCLs were heterozygous for the second polymorphism detected in this gene. 
This polymorphism is labeled with single letter code “S” (G or C). Allele “C” is present 
only in heterozygous state.  
 
To show that the identified polymorphism is not limited to the patient/donor pair, 
expression of the different allelic variants of the gene in the population was examined. 
cDNAs from 13 unrelated donors were obtained and sequenced (Table 3). In six cases the 
whole gene was sequenced, while in seven cases only the part spanning the polymorphism 
at position 636 (AK026923) was analyzed. Both nonsynonymous exchanges have been 
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detected in the cDNAs when the whole ORF was sequenced, whereas no additional 
polymorphisms were detected. Therefore, this method is capable to detect single 
nucleotide differences. At the first polymorphic position (184) (AK026923), three of the 
cDNAs are homozygous and carry allele “C”, one is homozygous and carries allele “T”, 
and two are heterozygous and carry both alleles. Therefore, both alleles are present with 
high frequency in the population and no additional alleles appear to exist. At position 636, 
eleven cDNAs are homozygous, and carry allele “G” whereas two are heterozygous and 
carry both alleles. No homozygous carrier of allele “C” was found. For precise 
determination of the allele frequency within the population, a larger number of individuals 
has to be examined. The data obtained so far indicates that allele “C” is present at low 
frequency in the population.  
   
 
N terminal 
position transmembrane region 
C terminal 
Position length 
193 
 
WLGWYTYML LPAALTGLLVFLSG
 
215 23 V
Table 4 
Predicted transmembrane region in antigen 21-1. The amino acid sequence of the 
predicted transmembrane domain is shown. The identified polymorphic amino acids are 
shown in colors. Valine (V) is present in the protein sequence of the donor, whereas the 
patient expresses two forms with either valine or leucine (L) at this position. 
 
In sequences obtained from LCLs #1, 3.3, GB, JM, #6, #7 and UB, a TCTC deletion was 
observed at position 383 (AK026923) in approximately 50% of the RT-PCR products. 
This deletion introduces a frameshift and a new premature stop codon, that probably 
represents a loss of function mutation. Because this deletion was not detected in the 
patient/donor pair, both alleles differing at position 636 (AK026923) in the ORF are 
expressed in frame, and therefore can induce immune responses after BMT. The SUSOI 
(http://sosui.proteome.bio.tuat.ac.j/about-sosui.html) program has been used for secondary 
structure prediction of the protein. This computational analysis predicted a transmembrane 
protein with seven transmembrane domains. InterPro (http://www.ebi.ac.uk 
/interpro/scan.html) database of protein domains and functional sites, which allows the 
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prediction of protein functions, did not give any results. The polymorphism detected 
between patient and donor resides within the first transmembrane domain (Table 4). 
Recently, a new gene has been deposited into GenBank with homology to antigen 21. This 
new gene codes for protein FLJ00159 (AK074088), and was cloned from human spleen 
(Fig. 14). The ORF is 5484 bp long and codes for a protein of 567 amino acids. This 
protein shares 102 amino acid with FLJ23270, and is predicted to contain three 
transmembrane domains. The first two transmembrane domains are identical in both 
proteins and encompass the nonsynonymous exchange detected in the patient/donor pair. 
The function of the protein is not known. 
Nonsynonymous exchange
 in donor/patient pair 
FLJ00159  
FLJ23270
ATG
GGC TGA
TGA
- Identical sequence in both genes     
- Transmembrane domain    
 
Fig. 14 
Nonsynonymous polymorphism between patient and donor in antigen 21-1. The 
polymorphism detected in antigen 21-1 is present in two different hypothetical proteins, 
designated FLJ00159 and FLJ23270 in the GenBank database (pos. 636, AK026923). The 
two different corresponding ORFs share the sequence shown in red, where the 
nonsynonymous exchange, relevant to GvL responses, was detected in the donor/recipient 
pair. Another nonsynonymous exchange at pos. 184 (AK026923) is not shown. Predicted 
transmembrane domains are depicted in both genes. The first gene codes for a protein 
containing three transmembrane domains, whereas the second gene codes for a protein 
containing six transmembrane domains. 
The second antigen of this group is encoded by clone 10 and designated 10-1. The 1.1kb 
cDNA insert is homologous to three mRNA GenBank entries (Acc.No. AK024488, 
XM_029084, and BC030281) form which three hypothetical proteins had been predicted 
(FLJ00087, FLJ21438 and alternatively spliced FLJ21438) (Table 2). As shown in Fig. 
15, clone 10 contains one of two ATG-defined ORFs predicted in FLJ00087 cDNA. 
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Whitin this ORF (10-1), a novel nonsynonymous exchange was detected by sequencing of 
patient (C/T) and donor (C) PCR products (pos.3001, AK024488), resulting in a 
corresponding exchange of arginine to cysteine (Table 2). All homologous GenBank 
entries (AK024488, XM_029084, and BC030281) demonstrate C at this position, 
corresponding to arginine in the protein sequence (Table 2). Thus, T cells, recognizing the 
mHA expressed from the patient allele “T”, are not negatively selected in the donor’ 
thymus and may cause GvH and/or GvL reactions in the BMT patient. In order to 
determine the allele frequency within the population, the ORF 10-1 was sequenced from 
ten unrelated individuals. Nine out of ten are homozygous and carry allele “C” whereas 
one is heterozygous and carries both alleles ”C/T”, indicating that the BMT patient is 
heterozygous for an allele which is found at low frequency within the population. 
Automated computational analysis demonstrated that antigen 10-1 is possibly soluble 
(SOSUI prediction method) and might represent a downregulator of ras-like proteins 
(GTP-ase acticator, RasGAP) (InterPro-based proteome analysis). RT-PCR analysis of the 
expression profile of antigen in the NEDO database indicates that the antigen might 
preferentially be expressed in the spleen (http://www.kazusa.or.jp/NEDO/gfpage/ 
FLJ00087/). 
 
Nonsynonymous exchange
in donor/patient pair  
FLJ00087
Clone 10
- C2 domain
TG AATG TAG 
TGA
ATG 
1972 3001 3361 4289792391
1
Nonsynonymous exchange in
donor/patient pair  
483 1872 2422 27981512
1336
GTG
1316
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Fig. 15  
Nonsynonymous exchanges between patient and donor in antigen 10-1 and 10-2. 
The cDNA insert of clone 10 was homologous to three mRNA GenBank entries (Acc.No. 
AK024488, XM_029084, and BC030281) from which three hypothetical proteins had 
been predicted (FLJ00087, FLJ21438 and alternatively spliced FLJ21438, respectively). 
The largest of all homologous mRNAs, FLJ00087, is depicted. This mRNA was predicted 
to contain two ATG-defined ORFs, designated here antigen ORF 10-1 and ORF 10-2, 
while the shorter, FLJ21438-related cDNAs contain ORF 10-1, only. When amplification 
of ORF-specific sequences from patient and donor tissue was performed using PCR, 
nonsynonymous polymorphisms were detected in both, ORF 10-1 (pos. 792, AK024488) 
and ORF 10-2 (pos. 3001, AK024488 and XM_029084, pos. 306, BC030281). ORF 10-1 
(pos. 39-1316) and ORF 10-2 (pos. 1927-3363) are likely to be efficiently translated, since 
the indicated ATG start codons are integrated in ideal (10-1) or nearly ideal (10-2) 
Koszak’s sequence (accATGg and gccATGg, respectively). The predicted ATG start 
codon of ORF-1, however, was not flanked by an upstream stop codon in the region up to 
pos. 1336 and, thus, an alternative upstream translation start site may be discussed, such as 
GTG at pos. 1459 or potential start sites located in upstream sequences spliced to ORF-1. 
Alternative translation from an upstream start codon would result in an extended N 
terminus of antigen 10-1 as indicated by dotted boxes. The potential alternative N 
terminus might contain a C2 domain (blue) involved e.g. in calcium-lipid binding as 
indicated by InterPro-based proteome analysis. Evidence for differential mRNA splicing 
of antigen-10-1, was provided by deleted 3’sequences in clone 10-1 compared to 
FLJ00087 as well as to both FLJ21438 mRNA variants. Accordingly, a very short (4aa) 
alternative COOH terminus was predicted. All positions indicated refer to Acc.No. 
AK024488 (FLJ00087) if not stated otherwise.  
 
A second, upstream ORF (10-2) was predicted in FLJ00087 mRNA and might thus 
encode a second antigen, designated here antigen 10-2. Sequence comparison between 
patient and donor identified a nonsynonymous exchange at position 792 (AK024488), 
resulting in an exchange of histidine to asparagine. Patient and donor are homozygous for 
different alles, with allele “G” in the patient and allele “C” in the donor. Automated 
computational analyses indicated that the antigen 10-2 might be soluble as well (SOSUI 
prediction method) and revealed two proline rich regions (InterPro-based proteome 
analsis) between which the nonsynonymous exchange is located (Fig.16). ORF 10-2 was 
sequenced from eleven unrelated individuals who all turned out to be homozygous for 
“C”, like the BM donor. 
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Proline-rich domain
NH 2 COOH
Nonsynonymous exchange
 in donor/patient pair
 
Fig. 16 
Nonsynonymous polymorphism between patient and donor in antigen 10-2. A 
single nonsynonymous exchange was detected and located between two proline reach 
regions.  
 
3.3.4. MHC class II epitope prediction 
 The mHA-specific T cell clones recognize four different antigens presented on 
three different HLA molecules. The binding cleft of MHC class II molecules contain nine 
so called pockets (minute indentations at the bottom of the cleft), each of which holds side 
chains of the amino acids in the peptide. Different side chains may have different effects 
on the binding affinity of the peptide; some may have positive (i.e. increase binding 
affinity), or negative (i.e. decrease binding affinity) while others may be neutral. Although 
the important binding positions are not well defined and appear to be different for different 
alleles, positions 3, 6 and 9 seem to be important for some MHC alleles. The minimal 
peptide length required for binding to different MHC class II molecules can vary from 9 to 
15 amino acids. One of the best-characterized HLA-DR alleles for peptide binding is 
DR11, which is also the restriction element of two of the T cell clones. The complete 
protein sequences of all three antigens were submitted for epitope prediction. In all three 
proteins, the identified polymorphisms are located inside epitopes predicted to bind to 
HLA-DR11 molecules (Fig 17). Moreover, the polymorphisms are located inside of so-
called “promiscuous binder” epitopes. These epitopes represent antigens or regions of an 
antigen that can bind to several HLA alleles. These regions are most suitable for vaccine 
development, because the immune response can be generated against a single epitope in a 
large population expressing different HLA molecules.  
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Antigen 10-1                                                     
                                                                                                                                                              ▼ 
DRB1_1101:TPLISKSQSLRSVRRSESWARPRPDEERPLRRPRPVQRTQSVPVRRPARRRQS 
DRB1_1102:TPLISKSQSLRSVRRSESWARPRPDEERPLRRPRPVQRTQSVPVRRPARRRQS 
DRB1_1104:TPLISKSQSLRSVRRSESWARPRPDEERPLRRPRPVQRTQSVPVRRPARRRQS 
DRB1_1106:TPLISKSQSLRSVRRSESWARPRPDEERPLRRPRPVQRTQSVPVRRPARRRQS 
DRB1_1107:TPLISKSQSLRSVRRSESWARPRPDEERPLRRPRPVQRTQSVPVRRPARRRQS 
DRB1_1114:TPLISKSQSLRSVRRSESWARPRPDEERPLRRPRPVQRTQSVPVRRPARRRQS 
DRB1_1120:TPLISKSQSLRSVRRSESWARPRPDEERPLRRPRPVQRTQSVPVRRPARRRQS 
DRB1_1121:TPLISKSQSLRSVRRSESWARPRPDEERPLRRPRPVQRTQSVPVRRPARRRQS 
DRB1_1128:TPLISKSQSLRSVRRSESWARPRPDEERPLRRPRPVQRTQSVPVRRPARRRQS 
 
 
 
Antigen 10-2                                                                                              
                                                                                                                           ▼ 
DRB1_1101:RDGPPSALGSRESLATLSELDLGAERDVRIWPLHPSLLGEPHCFQVTWTGGS 
DRB1_1102:RDGPPSALGSRESLATLSELDLGAERDVRIWPLHPSLLGEPHCFQVTWTGGS 
DRB1_1104:RDGPPSALGSRESLATLSELDLGAERDVRIWPLHPSLLGEPHCFQVTWTGGS 
DRB1_1106:RDGPPSALGSRESLATLSELDLGAERDVRIWPLHPSLLGEPHCFQVTWTGGS 
DRB1_1107:RDGPPSALGSRESLATLSELDLGAERDVRIWPLHPSLLGEPHCFQVTWTGGS 
DRB1_1114:RDGPPSALGSRESLATLSELDLGAERDVRIWPLHPSLLGEPHCFQVTWTGGS 
DRB1_1120:RDGPPSALGSRESLATLSELDLGAERDVRIWPLHPSLLGEPHCFQVTWTGGS 
DRB1_1121:RDGPPSALGSRESLATLSELDLGAERDVRIWPLHPSLLGEPHCFQVTWTGGS 
DRB1_1128:RDGPPSALGSRESLATLSELDLGAERDVRIWPLHPSLLGEPHCFQVTWTGGS 
 
 
 
Antigen 21-1                        
                                                        ▼ 
DRB1_1101:WLGWYTYMLVPAALTGLLVFLSGFSLFEASQISKEICEAHDILMCPLGDHSR 
DRB1_1102:WLGWYTYMLVPAALTGLLVFLSGFSLFEASQISKEICEAHDILMCPLGDHSR 
DRB1_1104:WLGWYTYMLVPAALTGLLVFLSGFSLFEASQISKEICEAHDILMCPLGDHSR 
DRB1_1106:WLGWYTYMLVPAALTGLLVFLSGFSLFEASQISKEICEAHDILMCPLGDHSR 
DRB1_1107:WLGWYTYMLVPAALTGLLVFLSGFSLFEASQISKEICEAHDILMCPLGDHSR 
DRB1_1114:WLGWYTYMLVPAALTGLLVFLSGFSLFEASQISKEICEAHDILMCPLGDHSR 
DRB1_1120:WLGWYTYMLVPAALTGLLVFLSGFSLFEASQISKEICEAHDILMCPLGDHSR 
DRB1_1121:WLGWYTYMLVPAALTGLLVFLSGFSLFEASQISKEICEAHDILMCPLGDHSR 
DRB1_1128:WLGWYTYMLVPAALTGLLVFLSGFSLFEASQISKEICEAHDILMCPLGDHSR 
 
 
 
Fig. 17 
 MHC class II binding peptide (http://www.imtech.res.in/raghava/propred/) 
prediction of the antigens 10-1, 10-2 and 21-1. The amino acid sequences have been 
submitted and the predicted peptides that bind to the HLA-DR 11 are shown in color. Red 
colored letters represent predicted amino acids that bind at position one in the binding 
groove of the HLA molecule (P1 binding amino acid). Binding prediction for all three 
antigens was done for nine different suballeles of HLA-DR11. Identical binding 
predictions were obtained when the alleles of the donor were submitted. Arrowheads 
indicate the position of the polymorphic amino acids.  
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3.3.5. Recognition assay 
In order to directly test whether the polymorphic antigens 10-1, 10-2, and 21-1 
identified by the SEREX method, are recognized by the CD4+ mHA-specific T cell clones, 
peptides spanning the polymorphic region were synthesized. Because the restriction 
molecules presenting the polymorphic peptides are not known, 15-mer peptides were 
synthesized with the polymorphic amino acid in the middle of the peptide. Peptides with 
this length should contain important binding amino acids for most of the HLA alleles. Six 
peptides have been synthesized (Fig. 18), covering the polymorphic region present in the 
patient and the donor. 
                                                             ▼ 
Peptide 10-1:                    TQSVPVRCPARRRQS          before BMT (patient) 
Control peptide 10-1:      TQSVPVRRPARRRQS         after    BMT (donor) 
 
 
                                                            ▼ 
Peptide 10-2:                   DVRIWPLDPSLLGEP           before BMT (patient) 
Control peptide 10-2:     DVRIWPLHPSLLGEP           after    BMT (donor) 
 
                                                               ▼ 
Peptide 21-1:                    GWYTYMLLPAALTGL        before BMT (patient) 
Control peptide 21-1:      GWYTYMLVPAALTGL       after    BMT (donor) 
 
Fig. 18 
15-mer peptides spanning the polymorphisms in the patient and the corresponding 
control peptides with the sequence from the donor were synthesized. Predicted binding 
motifs for DR11 are shown in blue. Amino acids shown in red are predicted P1 (amino 
acid that binds at position one in the binding groove of HLA molecule) binding amino 
acids. In the case of antigen 21, more predicted epitopes exists in the polymorphic region. 
Arrowheads indicate the polymorphic positions. 
 
Specific recognition assays were performed with the mHA-specific clones as 
effector cells and LCL donor, incubated with the peptides as target cells. None of the T 
cell clones recognized LCL donor incubated with any of these peptides (Fig. 19). 
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Fig. 19 
 
Peptide recognition assay. LCL patient incubated with peptides were used as a 
target cells for the mHA-specific T cell clones. Secretion of GM-CSF was determined by 
ELISA. 
 
 
The T cell clones isolated after BMT failed to recognize the polymorphic peptides. One 
possible explanation for this non-recognition could be that not all antigens were detected 
with the SEREX method, and that T cells specific for only a limited set of different  
 
antigens have been generated. Another explanation could be that the synthetic peptides are 
not long enough and lack amino acids that are important for binding to MHC class II 
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molecules or T cell recognition. An alternative explanation has recently been described for 
the mHA HA-8 (Brickner et al., 2001). The two allelic variants of HA-8, which differ in 
one amino acid, are differentially processed by the proteasome and the resulting peptides 
are transported with different efficiency by TAP into the endoplasmatic reticulum (ER). 
This leads to an inefficient presentation of one allelic variant on MHC class I. These 
results could offer an explanation why the peptides were not recognized by the mHA-
specific T cell clones. The polymorphisms may affect the processing of the proteins and 
thereby lead to the generation of different sets of peptides, but may not be directly 
recognized by the T cells. In order to test these possibilities, the specific recognition 
pattern of the mHA-specific T cell clones was compared with the allele transmission of the 
polymorphic antigens through the family (Fig. 8). Therefore, the ORFs of antigens 10, 10-
2 and 21 from twelve LCLs were amplified by RT-PCR and the polymorphic parts of all 
three genes sequenced. LCLs 1, 4, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 17 are homozygous 
for the identified polymorphisms in antigens 10, 10-2 and 21 and carry the same the alleles 
as the donor. Thus, the patterns of recognition and allele expression were not in 
accordance, indicating that the T cell clones probably recognize different antigens. 
 
3.3.6. Frequency of mHA-specific T cells 
The identification of a polymorphism between patient and donor does not 
necessarily imply an immunological importance of this antigen. Evidence for such 
immunological importance would be an increase in the frequency of T cells specific for 
this antigen after BMT in comparison to before BMT. In order to determine the frequency 
of T cells specific for these antigens after BMT, IFN-γ ELISPOT assays were performed. 
Due to limitations in the amount of PBL available from the patient, T cell lines stimulated 
3, 4 and 17 times with LCL patient were used. The T cell lines were tested against LCL 
patient and LCL donor. As expected, T cells restimulated 3 or 4 times contained a higher 
number of T cells specific for antigens presented on LCL patient than on LCL donor. 
These differences are lost after more passages because the T cells were restimulated with 
LCL that also very efficiently present EBV antigen. Consequently, EBV-specific or 
autoantigen-specific T cells dominate the T cell line after seventeen restimulations (Fig 
20).  
These data show that the T cell lines generated from PBL after BMT contain T cells 
specific for mHA, and T cells specific for EBV antigens.  
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IFN-g ELISPOT with T cell lines after BMT
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Fig  20 
IFN-γ ELISPOT assay with a representative T cells line (I) at passages p3, p4 and 
p17. The T cell line at p3 and p4 contains a higher frequency of T cells specific for 
antigens presented on LCL patient in comparison with LCL donor. These differences are 
lost after seventeen restimulations when EBV-specific T cells dominate the T cell line.  
 
In order to determine the frequency of T cells specific for the polymorphic 
peptides in these lines, ELISPOT assays were performed. To reduce the EBV background, 
PHA blasts obtained from the patient PBL after BMT were used as APCs instead of LCL. 
A transient increase in the frequency of T cells specific for all three polymorphic peptides 
was seen. This increase was not seen when a non-polymorphic control peptide were used 
in the same assay. As expected, this increase was lost after repeated T cell stimulations 
due to the domination of EBV-specific or autoantigen-specific T cells (Fig. 21). These 
experiments were repeted three times and indicated that T cells specific for the SEREX 
defined antigens are present after BMT, but they decrease in frequency after repeated 
stimulation in vitro.  
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Fig. 21 
 
IFN-γ ELISPOT assay performed with a representative T cell line (I) generated by 
stimulating PBL obtained after BMT with LCL patient taken at the indicated passage (p3, 
p4, and p17) and exposed to PHA blasts with or without peptides. A small but 
reproducible increase in the frequency of T cells specific for the three identified antigens 
was seen when the line was 3 and 4 times stimulated with LCL patient but not when 
stimulated 17 times. This increase was not seen with a non-polymorphic peptide. 
 
To enrich for these antigen-specific T cells, cytokine secretion and capture assays 
were performed. The T cell line p4 was stimulated with the three peptides for 16 hours. 
The cells were then labeled and separated using MACS MicroBeads. Positively selected 
cells were restimulated twice in order to obtain sufficient cell numbers and then tested in 
recognition assays. The same isolation procedure has been repeated four times 
independently. In all cases the isolated T cells recognized the peptides from the patient, 
but not the control peptides. Interestingly, neither LCL patient nor LCL donor were 
recognized (Fig. 21).  
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Fig. 22 
T cells specific for polymorphic antigens identified by SEREX method were 
successfully isolated from T cell line I p4 of the patient after BMT using cytokine 
secretion and capture assay. The isolated T cells specifically recognize peptides containing 
polymorphic amino acid sequence expressed in the patient but not control peptide 
containing amino acid sequence expressed in the donor. Non-selected fraction was tested 
against LCL patient and LCL donor and represents the control. 
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These experiments clearly demonstrated that T cells specific for polymorphic 
antigens identified with the SEREX method exist in the blood of the patient after BMT. 
Further characterisation of these T cells is underway. However, the T cell clones generated 
by repeated stimulation with LCL patient recognize different antigens than those defined 
by SEREX. Taken together, the SEREX method does not facilitate the molecular 
identification of the antigens recognized by mHA-specific T cell clones, but leads to the 
identification of a different set of mHA recognized by T helper cells as shown by early 
passage Th cell lines. 
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4. Discussion 
 
4.1. mHAs are recognize by T cells 
 
 
 mHA are the protein products of polymorphic genes, and peptides derived from 
mHA are presented on MHC class I and II for recognition by donor-derived mHA-specific 
CD4+ and CD8+ T cells. The development of techniques for cultivating T cells in vitro has 
allowed to isolate and expand mHA-specific T cells from the blood of patients after 
allogeneic BMT. These T cells have been used for the molecular identification of the 
genes that encode mHA. Current methods for the isolation of mHA-specific T cell usually 
rely on the stimulation of T cells taken from the patient after BMT with irradiated APC. 
For the generation of CD8+ mHA-specific T cell clones, different APCs including 
leukemia cells, PBL, DC, and LCLs have been successfully used. With this approach, T 
cell clones specific for a large number of different mHAs have been generated, suggesting 
that an even larger number mHAs exists.  
CD8+ T cells and CD4+ T cells play an important role in GvH and GvL responses 
after BMT (Jiang and Barrett J, 1997; Russell et al., 2001; Dodi et al., 2002; Zorn et al., 
2002). However, evidences for a pivotal role of CD4+ T cells in GvL induction without 
GvHD was obtained by the infusion of donor lymphocytes that had been depleted of CD8+ 
T cells (Giralt et al., 1995; Alyea et al., 1998). In the large study of Alyea et al. (1998), 
80% of the patients with relapsed hematological malignancies and subsequent CD4+ DLI 
showed clinical responses. All patients in this trial who developed GvHD demonstrated 
tumor regression, but the incidence of GvHD in responding patients was lower than 
reported for patients with tumor remission after infractionated DLI (Collins et al., 1997). 
Despite the importance of CD4+ T cells in the immune response after allogeneic 
BMT, only few CD4+ mHA-specific T cell clones have been isolated. Faber et al., 
generated CD4+ mHA-specific T cell clones with specificity for two different antigens 
(Faber et al., 1995). The same group recently reported the isolation of additional six CD4+ 
mHA-specific T cell clones (Eljaafari et al., 2001), demonstrating that mHA-specific 
CD4+ T cells exist, and that their isolation in vitro is feasible. Because of their 
unsurpassed T cell stimulatory capability, ideal APCs for the stimulation and isolation of 
mHA-specific CD4+ T cells are DC. DCs can be generated from precursor cells present in 
the blood of the patient and differentiated into DC in vitro.  
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4.2. Generation of CD4+ mHA-specific T cells 
 
In the present study it was not possible to collect enough material (PBL before 
BMT) for generating DC from the pediatric patient. Similar to DC, LCL express high 
levels of MHC class I and II, as well as costimulatory molecules. In contrast to DC, LCL 
can be generated from few milliliters of blood by EBV infection. LCLs represent 
immortalized B cells, which may proliferate infinitely in vitro, and thus provide enough 
cells of hematopoietic origin for all analyses performed in this work. In order to generate 
mHA-specific CD4+ T cells, PBL obtained from the patient after BMT, therefore, were 
stimulated with LCL generated from PBL before BMT. A number of CD4+ mHA-specific 
T cell clones were isolated using this protocol. LCL, however, not only present cellular 
antigens but also EBV antigens on MHC molecules. EBV-specific memory T cells are 
present in EBV-positive donors (Dolcetti et al., 1995; Hofmann et al., 2002), and EBV-
specific T cells will expand when repeatedly stimulated with LCL. ELISPOT assays were 
performed to follow the frequency of mHA-specific T cells in T cell lines established from 
the patient 3,5 months after BMT. T cell lines stimulated 3-4 times with LCL patient 
showed a high frequency of mHA-specific T cells. However, seventeen times stimulated 
PBL contain predominantly T cells that are EBV- or autoantigen-specific. These 
experiments demonstrated that mHA-specific donor T cells could be stimulated using 
EBV-transformed patient B cells. However, reactivation of EBV-specific T cell responses 
may occur and even overgrow mHA-specific T cell responses. Therefore, PBL from the 
patient obtained after BMT were stimulated only few times with irradiated LCLs. From 
these mHA-specific T cell lines, a large number of CD4+ mHA-specific T cell clones were 
isolated. These CD4+ mHA-specific T cell clones recognize four different antigens. Clone 
E10 III recognizes an antigen that is presented on HLA-DR11. Three LCLs positive for 
HLA-DR11 were not recognized by this T cell clone, suggesting that these three LCLs do 
not express the mHA. Most of the generated T cell clones showed this pattern of 
recognition, indicating that the antigen recognized represents an immunodominant mHA. 
Clone C3 III is also HLA-DR11 restricted, but all DR11 positive LCLs were recognized. 
This pattern of recognition shows that the C3 III clone recognizes a different antigen than 
clone E10 III, and that all family members express the mHA. Clone D5-3 II is HLA-DR52 
restricted, while clone F4 II is HLA-DQ6 restricted. Besides using different restriction 
elements, these T cell clones recognize a non-overlapping set of LCLs, and therefore 
recognize different antigens. FACS analysis and cytokine secretion assays showed that all 
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generated clones are of Th-1, and of memory phenotype. Two recent reports have 
suggested that Th-1 donor derived CD4+ T cells are responsible for the development of 
GvHD, whereas Th-2 cells are important for GvL responses and the prevention of GvHD 
(Fowler et al., 2000; Zeis et al., 2001). It remains to be seen, whether the exclusive 
generation of Th-1 type T cell clones in this study is due to a higher frequency of Th-1 
versus Th-2 cells, or whether the in vitro T cell culture conditions selectively favor Th-1 
cell expansion.  
Because generic methods for the identification of antigens presented on MHC class 
II are currently not available, only few antigens recognized by CD4+ T cells have been 
identified molecularly. By testing candidate mHAs identified previously as targets of 
CD8+ T cells, an epitope derived from DBY has recently been shown to be recognized by 
a mHA-specific CD4+ T cell clone (Vogt et al., 2002). No other MHC class II-restricted 
mHA has been identified. Therefore, an indirect approach was taken to identify the 
antigens recognized by the CD4+ T cell clones. In tumor patients, a close correlation 
between humoral and cellular immune responses has been observed (Jäger et al., 2000). In 
patients undergoing allogeneic BMT, little is known about humoral immune responses 
against tissue antigens. Increased numbers of circulating B cells and plasma cells have 
been observed in patients treated with DLI. A recent study assessed the targets of the 
humoral immune response in three patients with recurrent disease showing clinical 
response to DLI treatment (Wu et al., 2000). Interestingly, humoral immune responses 
against CHD-2 were observed in all three patients. CHD-2 was also identified as target of 
the antibody response in this study (clone # 8). No sequence comparison between patient 
and donor was performed in that study, therefore, it is not clear if any of the 13 identified 
antigens was polymorphic. Furthermore, since the expression library was established from 
tumor cells (CML), the observed sequence differences between the identified antigens and 
the GenBank database could be the results of tumor-specific alterations.   
 
4.3. SEREX method could be applied for identification of polymorphic antigens 
 
To examine the MHC class II-restricted T helper cell response after allogeneic 
BMT, the SEREX method was used to indirectly define the antigens involved in T helper 
cell response. Twenty antigens were identified in the patient/donor pair examined. 
Sequence analysis of the ORFs identified three antigens that are polymorphic between 
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donor and patient. While these antigens represent candidate mHAs, no polymorphism has 
been detected in the majority of antigens identified, and thus the remaining antigens could 
be autoantigens. In fact, many of the SEREX-defined antigens cloned from tumors were 
demonstrated to be autoantigens, since they were not only recognized by sera of tumor 
patients but by sera of healthy controls as well, as demonstrated by our group (Behrends et 
al., 2002; Behrends et al., 2003) and numerous others. After allogeneic BMT, a similarly 
high percentage of autoantigens might be identified since toxic conditioning regimes can 
cause significant tissue damage and possibly thereby lead to a secondary break down of 
immunotolerance. A simple method to directly detect and exclude autoantigens identified 
by SEREX after allogeneic BMT would be to test all antigens with serum collected from 
the patient before BMT and serum from the healthy donor. Unfortunately, such serum 
samples were not available in this study. However, immune responses against such “BMT-
associated autoantigens” might be transient and antibodies against these antigens might 
diminish over time. It will, therefore, be challenging, to test the identified antigens with 
serum collected at different time points after BMT and investigate any changes of the 
SEREX-antigen-specific humoral immune responses. Furthermore, by comparing antigens 
identified in a larger number of patient/donor pairs, a group of common BMT-associated 
autoantigens may be defined. Preliminary data obtained from one additional HLA-
identical BMT donor/patient pair suggests that ribosomal proteins may be such BMT-
associated autoantigens, because antibody responses against several ribosomal proteins 
were detected in both cases. Although ribosomal proteins are polymorphic in the 
population, they were identical in both patient and donor pairs examined. Another possible 
explanation for the apparent identification of many non-polymorphic antigens might be 
that these antigens are indeed polymorphic, but the polymorphisms were not detected.  
 
4.4. Identification of polymorphisms 
 
Polymorphisms between patient and donor were identified by comparing the 
cDNA sequences of the genes identified with the SEREX method. For this purpose, RNA 
was purified from T cells derived from patient and donor, reverse-transcribed into cDNA 
and then PCR amplified to obtain enough DNA for the sequencing reactions. Essential for 
this analysis, therefore, is precise RNA purification, cDNA preparation, and PCR 
amplification. By sequencing antigen 21-1 (FLJ23270) from several unrelated donors, a 
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four-nucleotide deletion was observed in 7 out of 10 cases, but not in the patient/donor 
pair. This deletion leads to a frameshift in the open reading frame and the appearance of a 
premature stop codon. This deletion was detected in about 50% of the cDNAs, and 
therefore, may be derived from one allele. These results indicated that both alleles are 
expressed equally, and this ratio was not affected by the preparation of cDNA.  
Polymorphisms in regulatory sequences of genes, however, may influence the level 
of transcription (Yamaguchi et al., 2002). Because PCR amplified mixes of cDNAs are 
sequenced, polymorphisms will only be detected if both alleles are transcribed at a similar 
level. Therefore, it cannot be excluded that polymorphisms were missed because the 
polymorphic allele is expressed at a lower level. Polymorphism analysis would not be 
affected by such differential gene expression, if the genes were analyzed at the DNA level. 
The copy numbers of both alleles would be the same and should be amplified by PCR in 
an equimolar ratio. However, for this kind of analysis, the genomic structure of the gene 
has to be known.  
Another possible explanation for the failure to detect polymorphisms could be that 
the polymorphisms are located in variants of the antigens created by alternative splicing. 
Because epitopes recognized by antibodies and T cells are not necessarily identical, it 
could be that a polymorphism is located in a splicing variant of the antigen, which has not 
been analyzed. For example, three different splicing variants of hematopoietic protein 1 
(HEM-1) were identified and additional variants may exist. Another example is the protein 
product derived from the sequence XM_031425 (clone 69), which shares 270 amino acids 
with the autoimmune regulator (AIRE) and therefore, may represent a splicing variant. 
AIRE plays an important role in central tolerance induction, probably by promoting the 
ectopic expression of peripheral tissue-restricted antigens in medullary epithelial cells of 
the thymus. A mutation in the transcription factor AIRE is responsible for the 
development of multiorgan autoimmune disease (Anderson et al., 2002). AIRE is 
exclusively expressed in thymic epithelial cells. The protein product from XM_031425 is 
also a transcription factor with unknown function and, because discovered in a cDNA 
library derived from T cells, with a different expression pattern. Further analysis of 
XM_031425 has to reveal whether this antigen plays any role in the immunological 
response after BMT. Finishing the human genome project will facilitate the identification 
of more splicing variants and will hopefully aid at answering this question.  
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4.5. T cells specific for polymorphic antigens are present in the blood of the patient 
 
Single nucleotide polymorphisms (SNPs) are common DNA sequence variations 
among individuals and in the last decade public databases containing several hundred 
thousands of SNPs have been established. Therefore, it is expected that SNP can be 
detected just by random comparison of 20 genes between two individuals. What are then 
the evidences that the polymorphic differences between the patient and the donor are not 
just polymorphisms detected by chance? After identification of the polymorphic antigens 
in the patient/donor pair, peptides carrying the allelic variants from patient and donor were 
synthesized. Evidence for an immunological importance of the identified polymorphic 
antigens would be the detection of T cells in transplanted patient which are specific for 
peptides derived from patient alleles compared control peptides derived from donor 
alleles. By using cytokine secretion and purification assays, T cells specific for all three 
polymorphic antigens were isolated. These T cells recognized the peptides carrying the 
allelic variant of the patient, but not the control peptides. These results demonstrated that 
T cells specific for the polymorphic antigens are present in the blood of the patient after 
BMT. Thus, the antigens identified by the SEREX method caused both humoral and 
cellular immune responses. Surprisingly, neither LCL obtained from the patient nor LCL 
obtained from the donor were recognized by these T cells. This unresponsiveness of the T 
cells to the LCLs may indicate that these antigens are inefficiently presented on MHC 
class II, and thereby may offer an explanation why the mHA-specific T cell clones 
generated by repeated stimulation with LCL patient did not recognize the polymorphic 
antigens identified with the SEREX method. Antigens presented on MHC class II are 
usually derived from exogenous proteins that have been internalized and degraded in the 
endosomal/lysosomal system. Besides exogenous antigens, endogenous antigens 
synthesized within the APC are also presented on MHC class II (Nuchtern et al., 1990; 
Chen et al., 1990). Recently, our group demonstrated that LCL can efficiently present a 
cytosolic protein on MHC class II (Nimmerjahn et al., 2003). The efficiency, however, by 
which endogenous antigens are presented on MHC class II, is dependent on the subcellular 
localisation as well as expression level and turnover rate of the protein. Intracellular 
antigens, therefore, are expected to be presented with varying efficiencies on MHC class II 
molecules. Activation and proliferation of T cells is dependent on antigen density, i.e. the 
number of MHC/antigen complexes presented on the cell surface. Consequently, T cells 
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specific for antigens which are efficiently presented on MHC class II will expand, while 
other T cell specificities may be lost under these in vitro culture conditions. These 
differences in antigen presentation may offer an explanation why no T cells specific for 
the SEREX-defined antigens have been generated, but do not explain why the antigens 
recognized by the T cell clones have not been identified by the serological approach. The 
SEREX method entails the expression of a protein library in E. coli. Bacterial expression 
of proteins is usually very efficient, but may be problematic in certain cases, e.g. 
membrane proteins which tend to aggregate, or proteins toxic to E. coli. Therefore, the 
expression level of some proteins may be too low for detection by serum antibodies. 
While expression of membrane proteins in E. coli appears to be difficult, proteins 
localized in the cell membrane very efficiently enter the MHC class II presentation 
pathway. Thus, it seems possible that the antigens recognized by the T cell clones are 
derived from membrane proteins, which are difficult to express in bacteria. Alternatively, 
the differences in the antigens identified with the serological and the cellular approach 
could be a reflection of the different methods used. The expression library used for 
screening with serum of the patient after BMT was prepared from T cells, whereas 
stimulation of the T cells was performed with LCL. Therefore, it is possible that the 
antigens identified by the SEREX method are not expressed in EBV-immortalized B cells 
used for T cell stimulation and vice versa. To address these possibilities, it will be 
important to examine protein expression level, protein turnover and localisation of the 
identified SEREX antigens in T and B cells.  
 
4.6. Frequency of polymorphic antigens in the population 
  
An immune response against mHAs after BMT is generated because they differ 
between patient and donor. Three antigens that are polymorphic between patient and 
donor were identified. Clone 10 contains two ORFs 10-1 and 10-2 and both are 
polymorphic. The protein product from ORF 10 has been described as FLJ00087 whereas 
the ORF 10-2 has been identified in this work. The cDNA encoding antigen 10-2 was 
homologous to mRNA FLJ00087 and two different splice variants. All three are found in 
hematopoietic tissues (blood, adult leukocytes and spleen), but the functions of the 
proteins they encode are not known. The sequence of clone 21-1 was found in two 
different genes (FLJ23270 and FLJ00159). Both are potential transmembrane proteins 
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with unknown functions, expressed in hematopoietic tissues, and both share the first 
transmembrane domain where the polymorphism is located. The clinical relevance of 
mHA is dependent on allele frequency within the population. For enhancement of immune 
responses against residual leukemia cells, patient and donor should differ in 
hematopoiesis-specific mHA. For example, two alleles of the hematopoiesis-specific 
mHA HA-1 have been identified in the human population. These two alleles, HA-1H 
(histidine) and HA-1R (arginine), are present within the population in 55.9% and 44.1%, 
respectively (Tseng et al., 1998). The HA-1H allele gives rise to an epitope that can be 
present on HLA-A2. Thus, a significant number of HLA-A2 positive patients would have 
an appropriately discordant donor for HA-1. The frequency for the two alleles of HA-2 is 
95% and 5%. Therefore, this mHA is suitable for enhancing GvL responses after BMT in 
only a small percentage of patients. HB-1 is presented on HLA-B44 and HB-1H (histidine) 
and HB-1Y (tyrosine) are present in 79% and 21% of the population, respectively. The 
allele frequencies for the three identified polymorphic antigens have been determined in 
this work by sequencing the polymorphic part of the genes in 13 unrelated volunteers. 
These experiments indicated, that the alleles identified are present at varying frequencies 
within the population. For example, antigen 21-1L (leucine, allele in patient) is present in 
15% of all individuals analyzed and is always found in a heterozygous state, whereas 21-
1V is present in 100% of the cases. Thus, in about 15% of the patient/donor pairs, 21-1L 
may play a role in the immune response after BMT. However, for statistical reasons, more 
individuals have to be examined. Sequence analysis of the ORFs, however, is time- and 
cost-consuming. Therefore, primers specific for the polymorphic part of the alleles will be 
generated, and the frequency of the various alleles analyzed by PCR in a larger number of 
cases.  
  Although allogeneic BMT has proven very effective for the treatment of certain 
malignancies, the treatment of tumor relapse is still difficult. DLI is used with great 
clinical success in patients with recurrent leukemia after BMT (Kolb et al., 1990; Kolb et 
al., 1995; Slavin et al., 1996; Kolb et al., 1997). However, the infusion of non-selected 
donor lymphocytes is very often associated with the development of GvHD. Different 
strategies have been used to prevent the development of GvHD but to preserve GvL 
reactivity in the infused lymphocytes. These strategies include: (i) titration of the infused 
T cell numbers, (ii) depletion of CD4+ or CD8+ T cell subsets, (iii) selective removal of 
alloreactive donor T cells, (iv) induction of T cell anergy specifically to alloantigens and, 
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(v) the introduction of suicide genes into the donor T cells. The thymidin kinase gene of 
herpes simplex virus (HSV-TK) has been transduced into T lymphocytes, which were then 
used in DLI. The development of GvHD could be efficiently reversed by the treatment of 
the patient with ganciclovir (Bonini et al., 1997). Tumor regression following DLI 
provides further evidence that T cells reactive against leukemia cells exist in the blood of 
the donor. Instead of using unselected lymphocytes, the infusion of T cells specific to 
hematopoiesis-specific mHA expanded in vitro may lead to the eradication of residual 
leukemia cells after BMT without inducing GvHD. Such adoptive transfer of T cell clones 
has been successfully applied to reconstitute CMV and EBV immunity in 
immunocompromised patients (Walter et al., 1995; Gahn et al., 2002). Another possibility 
to specifically prime immune responses against antigens expressed on leukemia cells is by 
active vaccination. For this purpose, well defined, sufficiently immunogenic, 
hematopoiesis-specific mHA have to be identified. Whether the mHA identified in this 
work recognize ubiquitously expressed, or hematopoiesis-specific mHA, still has to be 
determined. 
 
4.7. Conclusions 
  
 It has been shown in this work that minor histocompatibility antigens can be 
identified by serological screening of a cDNA expression library generated from normal 
tissue of the patient. Furthermore, T cell culture conditions have been established and 
optimized to efficiently generate CD4+ mHA-specific T cell lines and clones. The antigens 
identified with the modified SEREX approach were not recognized by the mHA-specific T 
cell clones. Thus, these two approaches have led to the definition of a complementary 
rather than an overlapping set of antigens. Further analyses are required to see whether 
this holds true in a larger number of patient/donor pairs, and whether the antigens 
identified are unique to the patient/donor pair examined, or shared among recipients of 
allogeneic BMT. In summary, immunotherapeutic approaches to enhance GvL and reduce 
GvH responses after allogeneic BMT are greatly dependent on the molecular definition of 
mHA. Methods for the definition of mHA recognized by CD4+ T cells, as described in this 
work, may help to achieve this goal.  
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Summary 
 
 
After allogeneic HLA-identical BMT, the cells of the new immune system 
recognize peptides derived from mHAs in which patient and donor differ. The 
identification of mHAs therefore, is important for the development of immunotherapeutic 
approaches, which aim at enhancing GvL and decreasing GvH responses. Since T helper 
cells play a central role in various immune responses, mHA recognized by Th cells are of 
special interest. 
In order to identify mHAs recognized by T helper cells, a dual strategy was 
designed to define the targets of the T helper cell response after BMT. In a serological 
approach to define the targets of the humoral immune response, 20 different antigens were 
identified. By comparing patient and donor mHA sequences, three antigens were found to 
have interindividual differences. Furthermore, analysis of unrelated individuals confirmed 
that these antigens are polymorphic in the population. To assess the targets of the cellular 
immune response, a number of mHA-specific T cell lines and clones were generated. 
These T cell clones were all CD4+ and of Th-1 phenotype, and recognized four different 
mHAs presented on three different HLA molecules. Specific recognition assays showed 
that these clones do not recognize mHAs identified as the targets of humoral immune 
response. The recognition pattern of the mHA-specific T cell clones did not correlate with 
the distribution of polymorphic alleles within unrelated donors, confirming that antibodies 
and T cells recognize different mHAs. However, increased numbers of T cells specific for 
these antigens were found in the blood of the patient after BMT. The detection and 
successful isolation of these T cells provides further evidence that these antigens are 
important in the immune response after BMT. 
 This work shows that mHAs recognized by T helper cells can be identified through 
serological methods. The method applied here, however, did not lead to the identification 
of mHAs recognized by independently generated mHA-specific T cell clones. It remains 
to be seen whether antigens identified by these two approaches are different or 
overlapping in a larger number of patient/donor pairs. Furthermore, analysis of a larger 
number of patient/donor pairs should reveal whether the antigens identified with these two 
approaches are unique to the analysed patient/donor pair, or shared among several 
patient/donor pairs. The latter set of antigens could be especially useful for increasing GvL 
and decreasing GvH responses.  
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Abbreviations 
 
 
AIRE    autoimmune regulator 
AP     alkaline phosphatase  
APC      antigen-presenting cell  
bp     base pair  
BM    bone marrow 
BMT    bone marrow transplantation  
BSA      bovine serum albumine  
cDNA     complementary DNA  
CHD    chromodomain helicase 
CML    chronic myeloid leukemia 
CMV      cytomegalovirus  
CTL    cytotoxic T cells 
CTL      cytotoxic T lymphocytes  
DC    dendritic cell 
DLA    dog leukocyte antigens 
DLI    donor lymphocytes infusion 
DMSO      dimethylsulfoxyde  
dNTP     desoxyribonucleotide  
DTT      dithiothreitol  
EBV    Epstein-Barr virus 
E. coli      Escherichia coli  
EEF1A1    eukaryotic translation elongation factor 1 alpha 1  
EGF    epidermal growth factor 
EDTA      (Titriplex III) ethylenediaminetetraacetic acid  
ELISA      enzyme-linked immunosorbent assay 
ELISPOT   enzyme-linked immunospot assays 
FACS      fluorescent activated cell sorter  
FCS      fetal calf serum  
FITC     fluorescein isothiocyanate  
GM-CSF   granulocyte macrophage colony stimulating factor 
GvL    graft-versus-leukemia  
GvHD    graft-versus-host disease 
HEM    hematopoietic protein 
HLA    human leukocyte antigens 
HPLC    high performance liquid chromatography  
HSV-TK   herpes simplex virus-thymidin kinase 
ICAP    integrin cytoplasmic domain-associated protein 
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IFNγ    interferon gamma  
Ig      immunoglobulin  
IL-4     interleukin 4  
INF    interferon 
IPTG     isopropyl-1-thio-β-D-galactoside  
kb     kilobase pairs  
LB-agar    Luria Bertani-agar 
LCL    lymphoblastoid cell line 
mHA    minor histocompatibility antigens 
MHC      major histocompatibility complex  
MOPS    3-[N-morpholino]propane-sulfonic acid 
MuMLV   mouse moloney leukaemia virus 
mRNA     messenger RNA  
OD     optical density  
ORF     open reading frame 
pAPC    professional antigen presenting cells 
PE    phycoerythrin 
PBL    peripheral blood lymphocytes 
PBS    phosphate buffered saline 
PCR      polymerase chain reaction  
PHA    phytohemagglutinin 
PR-3    proteinase-3 
rpm      rotations per minute  
RT     room temperature  
RT-PCR     reverse transcriptase polymerase chain reaction  
SEREX    serological analysis of recombinant cDNA expression libraries 
SDS     sodium dodecylsulfate  
SNP    single nucleotide polymorphisms 
TAE    Tris-Acetate-EDTA 
TAP     transporter associated with antigen processing 
TBE      Tris-boric EDTA buffer  
TBI    total body irradiation 
TBS    Tris-Buffered Saline 
TE    Tris-EDTA 
TCR     T cell receptor 
TEMED    N,N,N’,N’-Tetramethylethylendiamin 
TERT    telomerase reverse transcriptase 
Th1, Th2     T helper cell type 1 or 2  
Tween 20    polyoxyethylene sorbitane monolaurate  
U     units 
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VPS    vacuolar sorting protein 
WT-1    Wilm's tumor gene 
x-gal    5-Bromo-4-Chloro-3-Indoyl--D Galactopyranosid 
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